Page last updated: 2024-12-08

paromomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID165580
CHEMBL ID370143
CHEBI ID7934
SCHEMBL ID4072
MeSH IDM0015969

Synonyms (82)

Synonym
r-400
CHEMBL370143
antibiotic sf-767b
chebi:7934 ,
hatt & paromomycin
human .alpha.-1-antitrypsin & paromomyin
(1r,2r,3s,4r,6s)-4,6-diamino-2-{[3-o-(2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl)-beta-d-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside
o-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-[o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.d-ribofuranosyl(1->5)]-2-deoxy-d-streptamine
aminosidine, sulfate
humatin
(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-hydroxy-cyclohexoxy]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-tetrah
paramomycin sulfate
monomycin
paromomycin
neomycin e
monomycin a
aminosidin
7542-37-2
catenulin
hydroxymycin
zygomycin a1
C00832
estomycin
aminosidine
crestomycin
DB01421
paucimycin
gabbromycin
paromomycine
gabromycin
amminosidin
humycin
d-streptamine, o-2-amino-2-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-beta-d-ribofuranosyl-(1-5))-2-deoxy-
brn 0072285
einecs 231-423-0
paromomycine [inn-french]
streptamine, o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-o-beta-d-ribofuranosyl-(1-5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1-4))-2-deoxy-
paromomycinum [inn-latin]
paramomycin
aminosidine i
paromomicina [inn-spanish]
antibiotic sf 767b
antibiotic 503-3
r 400
paucimycinum
antibiotic 2230d
quintomycin c
paromomycin (tn)
D07467
paromomycin (inn)
(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol
paromomycinum
paromomicina
paromomycin [inn:ban]
61jjc8n5zk ,
paromomycin [inn]
4-18-00-07534 (beilstein handbook reference)
unii-61jjc8n5zk
d-streptamine, o-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.-d-ribofuranosyl-(1->5))-2-deoxy-
o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine
paromomycin [who-dd]
o-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.-d-ribofuranosyl-(1->5))-2-deoxy-d-streptamine
paromomycin [vandf]
neomycin sulfate impurity e [ep impurity]
diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine
paromomycin [mi]
UOZODPSAJZTQNH-LSWIJEOBSA-N
SCHEMBL4072
AB00639998_04
DTXSID8023424
(2r,3s,4r,5r,6s)-5-amino-6-{[(1r,2r,3s,4r,6s)-4,6-diamino-2-{[(2s,3r,4s,5r)-4-{[(2r,3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}-2-(hydroxymethyl)oxane-3,4-diol
AKOS030489917
paromomycin i; amminosidin; catenulin; crestomycin; monomycin a; neomycin e
Q415625
(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-(((2r,3s,4r,5s)-5-(((1r,2r,3s,5r,6s)-3,5-diamino-2-(((2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)
134235-09-9
sf 767b; catenulin; crestomycin; gabbromicina
NCGC00166210-02
gtpl12160
d-streptamine, o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1-.4))-2-deoxy-
EN300-122625
(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-{[(2r,3s,4r,5s)-5-{[(1r,2r,3s,5r,6s)-3,5-diamino-2-{[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol

Research Excerpts

Overview

Paromomycin is a 2-deoxystreptamine aminocyclitol aminoglycoside antibiotic with broad spectrum activity against Gram-negative, Gram-positive bacteria and many protozoa. It was first isolated in the 1950s, and approved in 2006 for treatment of visceral leishmaniasis.

ExcerptReferenceRelevance
"Paromomycin is an aminoglycoside antibiotic approved in 2006 for the treatment of visceral leishmaniasis caused by Leishmania donovani in Southeast Asia. "( Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo.
Branco, N; Coelho, AC; Coser, EM; Ferreira, BA; Lindoso, JAL; Yamashiro-Kanashiro, EH, 2020
)
2.38
"Paromomycin is an aminoglycoside antibiotic that has already been approved for the treatment of visceral leishmaniasis in Southeast Asia."( Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil.
Coelho, AC; Coser, EM; Ferreira, BA; Lindoso, JAL; Yamashiro-Kanashiro, EH, 2021
)
1.68
"Paromomycin is a 2-deoxystreptamine aminocyclitol aminoglycoside antibiotic with broad spectrum activity against Gram-negative, Gram-positive bacteria and many protozoa. "( Production and statistical optimization of Paromomycin by Streptomyces rimosus NRRL 2455 in solid state fermentation.
Aboshanab, KM; El-Housseiny, GS; Ibrahim, AA; Yassien, MA, 2021
)
2.33
"Paromomycin sulphate (PM) is a promising antileishmanial drug."( Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.
Badirzadeh, A; Doroud, D; Habibzadeh, S; Heidari-Kharaji, M; Rafati, S; Taheri, T, 2016
)
1.57
"Paromomycin is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. "( Paromomycin.
Davidson, RN; den Boer, M; Ritmeijer, K, 2009
)
3.24
"Paromomycin is an aminoglycoside antibiotic with activity against protozoa. "( Pilot study on the efficacy of paromomycin as a histomonostatic feed additive in turkey poults experimentally infected with Histomonas meleagridis.
De Gussem, K; Gad, W; Hafez, HM; Hauck, R; Lotfi, A, 2010
)
2.09
"Paromomycin was shown to be an efficacious first-line treatment with low toxicity in India."( Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
Ahmed, O; Alobo, M; Balasegaram, M; Edwards, T; El-Hassan, A; Ellis, S; Fadlalla, A; Hailu, A; Hailu, W; Hurissa, Z; Kesusu, J; Khalil, E; Kinuthia, J; Kirigi, G; Kirui, F; Koummuki, Y; Lodenyo, H; Makonnen, E; Manduku, V; Mbui, J; Mengistu, G; Mucee, G; Mueller, M; Musa, A; Musibi, A; Mutea, D; Muthami, L; Mutuma, G; Njoroge, S; Omollo, R; Owiti, R; Raheem, M; Rashid, J; Royce, C; Smith, P; Tesfaye, S; Wasunna, M; Weldegebreal, T; Yifru, S, 2010
)
1.32
"Paromomycin (PM) is an aminoglycoside antibiotic, first isolated in the 1950s, and approved in 2006 for treatment of visceral leishmaniasis. "( Characterization, thermal stability studies, and analytical method development of Paromomycin for formulation development.
Khan, W; Kumar, N, 2011
)
2.04
"Paromomycin is an aminoglycosidic antibiotic that targets the RNA of the bacterial small ribosomal subunit. "( Understanding the origins of bacterial resistance to aminoglycosides through molecular dynamics mutational study of the ribosomal A-site.
McCammon, JA; Romanowska, J; Trylska, J, 2011
)
1.81
"Paromomycin is an aminoglycosidic antibiotic and is one of the drugs currently being used in the chemotherapy of cutaneous and visceral leishmaniasis."( Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani.
Chawla, B; Jhingran, A; Madhubala, R; Panigrahi, A; Stuart, KD, 2011
)
2.53
"Paromomycin appears to be an effective drug for treatment of D."( Treatment of Dientamoeba fragilis infection with paromomycin.
Dediste, A; Mouchet, F; Souayah, H; van Gool, T; Vandenberg, O, 2007
)
1.32
"So, paromomycin is a good candidate for field trials because it is prophylactically effective against experimental C."( Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study.
Chartier, C; Mancassola, R; Naciri, M; Reperant, JM, 1995
)
1.02
"Paromomycin appeared to be an active and well-tolerated treatment for cryptosporidiosis in patients with AIDS."( Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS.
Bissuel, F; Cotte, L; Piens, MA; Rabodonirina, M; Rougier, P; Trepo, C, 1994
)
2.45
"Paromomycin is an aminocyclitol aminoglycoside antibiotic used for the treatment of leishmaniasis. "( In vivo interference of paromomycin with mitochondrial activity of Leishmania.
Brown, S; de Kouchkovsky, Y; Maarouf, M; Petit, PX; Robert-Gero, M, 1997
)
2.05
"Paromomycin is an antileishmanial chemotherapeutic agent. "( Development and characterization of paromomycin-resistant Leishmania donovani promastigotes.
Adeline, MT; Maarouf, M; Robert-Gero, M; Solignac, M; Vautrin, D, 1998
)
2.02
"Paromomycin is a promising therapy for cryptosporidiosis in acquired immunodeficiency syndrome and further prospective clinical trials are warranted."( Treatment of cryptosporidiosis with paromomycin. A report of five cases.
Armitage, K; Carey, J; Flanigan, T; Frank, I; Goodgame, R; MacGregor, RR; Ross, P; Turner, J, 1992
)
1.28
"Paromomycin is a nonabsorbable aminoglycoside that is effective in the treatment of other intestinal protozoa."( Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line.
Flanigan, TP; Marshall, RJ, 1992
)
2.45

Effects

Parmomycin has no effect if native tRNA(Arg(ICG) is highly expressed. Paromomycin sulphate (PM) has been shown to be efficacious for VL treatment in India. emergence of drug resistance can only be appropriately judged upon its long term routine use.

ExcerptReferenceRelevance
"Paromomycin has no effect if native tRNA(Arg(ICG)) is highly expressed, consistent with the idea that failure to efficiently decode CGA codons might occur in part due to rejection of the cognate tRNA(Arg(ICG))."( Translation of CGA codon repeats in yeast involves quality control components and ribosomal protein L1.
Brule, CE; Grayhack, EJ; Letzring, DP; Wolf, AS, 2013
)
1.11
"Paromomycin has recently been introduced for the treatment of visceral leishmaniasis and emergence of drug resistance can only be appropriately judged upon its long term routine use in the field. "( Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.
Cos, P; Delputte, P; Dujardin, JC; Hendrickx, S; Khanal, B; Leemans, A; Maes, L; Mondelaers, A; Rijal, S, 2015
)
2.08
"Paromomycin (PR) has been developed as an alternative to SbV, but existing data are conflicting."( Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
Bleys, J; Chung, HJ; Ghohestani, RF; Kim, DH, 2009
)
1.7
"Paromomycin (PMM) has recently been introduced for treatment of visceral leishmaniasis in India. "( Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
Bhandari, V; Carter, K; Cos, P; Dujardin, JC; Hendrickx, S; Inocêncio da Luz, RA; Kuypers, K; Lonchamp, J; Maes, L; Rijal, S; Salotra, P; Shaw, CD; Sundar, S, 2012
)
2.12
"Paromomycin sulphate (PM) has been shown to be efficacious for VL treatment in India."( Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
Abuzaid, AA; Ahmed, O; Apadet, L; Balasegaram, M; Edwards, T; El-Hassan, A; Ellis, S; Fadlalla, A; Hailu, A; Hailu, W; Hurissa, Z; Kesusu, J; Khalil, E; Kimutai, R; Kirigi, G; Lodenyo, H; Makonnen, E; Manduku, V; Mbui, J; Mekonnen, Y; Mengistu, G; Mucee, G; Mueller, M; Musa, A; Musa, B; Mutea, D; Mutuma, G; Ndegwa, S; Njoroge, S; Olobo, J; Omollo, R; Owiti, R; Rashid, J; Sagaki, P; Tafes, H; Wasunna, M; Weldegebreal, T; Yifru, S, 2012
)
1.39

Actions

Pomomycin may cause temporary tubular damage leading to calcium wasting in urine and hypocalcaemia resulting in tetany. It did not inhibit the binding of IF3 to the 30S ribosomal subunits.

ExcerptReferenceRelevance
"Paromomycin did not inhibit the binding of IF3 to the 30S ribosomal subunits."( Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
Hirokawa, G; Kaji, A; Kaji, H, 2007
)
1.29
"Paromomycin exposure was lower in paediatric patients compared with adults [median (IQR) end-of-treatment AUC0-24h 187 (162-203) and 242 (217-328) µg·h/mL, respectively], but were both within the IQR of end-of-treatment exposure in Kenyan and Sudanese adult patients from a previous study."( Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M, 2023
)
1.87
"Paromomycin may cause temporary tubular damage leading to calcium wasting in urine and hypocalcaemia resulting in tetany."( Tetany in kala azar patients treated with paromomycin.
Thakur, CP, 2008
)
1.33

Treatment

Treatment with paromomycin (25-35 mg/kg/d for 7 days) was evaluated prospectively in 15 children with Dientamoeba fragilis infection. Treatment was well tolerated by all patients with the exception of two, who experienced nausea and abdominal discomforation.

ExcerptReferenceRelevance
"Paromomycin-based topical treatments were shown to be effective in curing cutaneous leishmaniasis (CL) lesions caused by Leishmania major in Tunisia. "( Topical paromomycin for New World cutaneous leishmaniasis.
Adams, RC; Grogl, M; Jiménez, AI; Kreishman-Detrick, M; Lawrence, K; McCarthy, WF; Norwood, JA; Pascale, JM; Ransom, J; Scott, C; Sosa, N; Tang, D; Weina, PJ, 2019
)
2.39
"Paromomycin treatment did not negatively affect the growth of chili pepper."( Paromomycin Derived from Streptomyces sp. AG-P 1441 Induces Resistance against Two Major Pathogens of Chili Pepper.
Balaraju, K; Kim, CJ; Nam, KW; Park, DJ; Park, K; Sang, MK; Zhang, K, 2016
)
2.6
"Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS."( Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial.
Chappell, CL; Flanigan, TP; Goodgame, RW; Hayat, CS; Kimball, KT; White, AC, 1994
)
2.45
"Paromomycin treatment was very effective against villus surface infections in suckling mice and considerably less effective against infections in inaccessible sites such as abscessed crypts and stomach pits seen in weaned and adult scid mice."( Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin.
Crabb, J; Griffiths, J; Rand, W; Tzipori, S; Widmer, G, 1994
)
1.23
"Treatment with Paromomycin resulted in different outcomes, perhaps because patients harbored other intestinal parasitic infections."( Cryptosporidium species from human immunodeficiency-infected patients with chronic diarrhea in Jakarta, Indonesia.
Connelly, L; Djauzi, S; Dwintasari, SW; Karyadi, T; Kurniawan, A; Nichols, RA; Yunihastuti, E, 2013
)
0.73
"Treatment with paromomycin (25-35 mg/kg/d for 7 days) was evaluated prospectively in 15 children with Dientamoeba fragilis infection after 1-month follow-up. "( Treatment of Dientamoeba fragilis infection with paromomycin.
Dediste, A; Mouchet, F; Souayah, H; van Gool, T; Vandenberg, O, 2007
)
0.95
"Treatment with paromomycin was well tolerated by all patients with the exception of two, who experienced nausea and abdominal discomfort."( Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS.
Fichtenbaum, CJ; Powderly, WG; Ritchie, DJ, 1993
)
1.08

Toxicity

ExcerptReferenceRelevance
" One patient (SB alone) had experienced a serious adverse event: cardiotoxicity at day 8 (myocarditis and ECG changes) which caused withdrawal from the study."( A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.
Houlihan, HH; Kanyok, TP; Olliaro, P; Pandey, AK; Sinha, GP; Thakur, CP; Zaniewski, AE,
)
0.35
" However, severe toxic side effects along with the reduced suppression efficiency at subtoxic doses limit the use of gentamicin for suppression therapy."( Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
Baasov, T; Belakhov, V; Ben-Yosef, T; Chen, F; Cherniavsky, M; Hainrichson, M; Nudelman, I; Pilch, DS; Rebibo-Sabbah, A; Schacht, J, 2009
)
0.35
"7%) experienced possible adverse effects, the most common being diarrhea (17/123, 13."( Efficacy and safety of paromomycin for treating amebiasis in Japan.
Kikuchi, T; Kimura, M; Koga, M; Maruyama, H; Miura, T; Shimizu, S, 2013
)
0.7
" More research on adverse drug events for the existing drugs and efforts to develop safer and effective drugs to counter resistance outbreaks for the successful management of visceral leishmaniasis are needed."( The treatment of visceral leishmaniasis: safety and efficacy.
Jha, RK; Sah, AK; Sah, P; Shah, DK,
)
0.13
" VL patients treated using the new treatment were consented and included in a common registry that collected demographics, baseline clinical characteristics, adverse events, serious adverse events and treatment outcomes."( Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
Alirol, E; Alvar, J; Alves, F; Balasegaram, M; Chappuis, F; Diro, E; Ellis, S; Hailu, A; Jameneh, A; Khalil, EA; Kimutai, R; Makonnen, E; Mohammed, R; Musa, AM; Musa, B; Njoroge, S; Okello, L; Olobo, J; Omollo, R; Rashid, J; Ritmeijer, K; Sagaki, P; Salman, K; Soipei, P; Strub, N; Wasunna, M, 2017
)
0.7
" SSG-PM was effective and safe except in HIV/VL co-infected or older patients."( Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
Alirol, E; Alvar, J; Alves, F; Balasegaram, M; Chappuis, F; Diro, E; Ellis, S; Hailu, A; Jameneh, A; Khalil, EA; Kimutai, R; Makonnen, E; Mohammed, R; Musa, AM; Musa, B; Njoroge, S; Okello, L; Olobo, J; Omollo, R; Rashid, J; Ritmeijer, K; Sagaki, P; Salman, K; Soipei, P; Strub, N; Wasunna, M, 2017
)
0.7
" Combination regimens including AmBisome, paromomycin and miltefosine have proved to be safe and effective in the treatment of VL in India."( Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N, 2017
)
0.94
" There were 12 serious adverse events in the study in 11 patients that included 3 non-study drug related deaths."( Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N, 2017
)
0.68
" This study aimed to investigate the feasibility of using focused pharmacovigilance for VL (VLPV) in Bangladesh's National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions (ADRs)."( Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018
)
0.48
" A VLPV expert committee and a UHC VLPV team were established, an operational manual and pharmacovigilance report forms were developed, training and refresher training of health personnel took place at UHCs and at the central level, collected information such as patient data including demographics, treatment history and response, adverse events were analyzed."( Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018
)
0.48
" Thirteen serious adverse events (SAEs) (eight deaths and five unexpected SAEs) were observed."( Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018
)
0.48
" All three regimens were safe, with 5 severe adverse events in the SDA arm, two of which were considered to be drug related."( Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
Alvar, J; Alves, F; Balasegaram, M; Bern, C; Burza, S; Das, P; Ellis, S; Goyal, V; Hightower, A; Lima, N; Mahajan, R; Pandey, K; Rabi Das, VN; Rijal, S; Sharma, B; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T; Topno, RK, 2018
)
0.48
" The full repertoire of cellular targets and processes leading to the toxicity of aminoglycosides is not fully resolved, making it challenging to devise rational directions to circumvent their adverse effects."( The relationship between the structure and toxicity of aminoglycoside antibiotics.
Fridman, M; Jospe-Kaufman, M; Siomin, L, 2020
)
0.56
" The most common adverse events (AEs) were raised liver transaminases (35."( Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
Atnafu, S; Hailu, A; Medhin, G; Mohammed, R; Tamiru, A, 2021
)
0.83
"A combination of SSG at 20mg/kg with upper daily maximum dose of 850mg and PM was effective for achieving initial cure at end of treatment and safe for treatment of HIV negative VL patients in northwestern Ethiopia."( Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
Atnafu, S; Hailu, A; Medhin, G; Mohammed, R; Tamiru, A, 2021
)
0.83

Pharmacokinetics

A population pharmacokinetic model was developed for paromomycin in Eastern African and Indian VL patients. The model provides detailed insight into the pharmacokinetics differences among Eastern African countries and India. However, the resulting differences do not seem to explain the geographical differences in parommycin efficacy in the treatment of VL Patients.

ExcerptReferenceRelevance
" Compartmental and noncompartmental pharmacokinetic parameters were estimated with the microcomputer program WinNonlin."( Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects.
Danziger, LH; Kanyok, TP; Killian, AD; Rodvold, KA, 1997
)
0.3
" The developed bioanalytical method was validated and applied for pharmacokinetic studies of PM administered by intramuscular and intravenous routes as well as for developed PM-MS which were administered by intravenous route."( Bioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheres.
Khan, W; Kumar, N; Sharma, SS, 2013
)
0.62
" Pharmacokinetic parameters for gentamicin could not be calculated because detectable levels were rarely evident."( Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.
Grogl, M; Kopydlowski, KM; Kreishman-Deitrick, M; Lin, YJ; Llanos-Cuentas, A; Nielsen, C; Ransom, JH; Ravis, WR; Smith, KS; Smith, PL; Sosa, N, 2013
)
0.67
" The objective of this study was to determine the pharmacokinetic profile and the safety of aminosidine in dogs with naturally occurring leishmaniosis and in healthy dogs after once daily administration."( Pharmacokinetics and tolerability of aminosidine after repeated administrations using an optimal dose regimen in healthy dogs and in dogs with leishmaniosis.
Athanasiou, LV; Batzias, GC; Delis, G; Kontos, VI; Rallis, TS; Saridomichelakis, MN; Soubasis, N, 2014
)
0.4
" A population pharmacokinetic model was developed for paromomycin in Eastern African and Indian VL patients."( Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.
Alves, F; Aman, R; Beijnen, JH; Chakravarty, J; Dorlo, TPC; Hailu, A; Hailu, W; Huitema, ADR; Hurissa, Z; Khalil, EAG; Kokwaro, G; Kshirsagar, SA; Makonnen, E; Mekonnen, Y; Mudawi, M; Musa, AM; Rai, M; Sundar, S; Tesfaye, S; Verrest, L; Wasunna, M; Younis, BM, 2021
)
1.16
"The developed model provides detailed insight into the pharmacokinetic differences among Eastern African countries and India, however the resulting differences in paromomycin exposure do not seem to explain the geographical differences in paromomycin efficacy in the treatment of VL patients."( Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.
Alves, F; Aman, R; Beijnen, JH; Chakravarty, J; Dorlo, TPC; Hailu, A; Hailu, W; Huitema, ADR; Hurissa, Z; Khalil, EAG; Kokwaro, G; Kshirsagar, SA; Makonnen, E; Mekonnen, Y; Mudawi, M; Musa, AM; Rai, M; Sundar, S; Tesfaye, S; Verrest, L; Wasunna, M; Younis, BM, 2021
)
1.11
" Population pharmacokinetic models were developed."( Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M, 2023
)
1.15
"Data from 265 patients (59% ≤12 years) were available for this pharmacokinetic analysis."( Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M, 2023
)
1.15

Compound-Compound Interactions

Imiquimod combined with either paromomycin (25, 50 and 100 microg/ml) or methylbenzethonium chloride (0.0%) increased inhibitory effect. In 2002, we replaced the standard regimen of 30 days of daily sodium stibogluconate (SSG) with a 17-day regimen of daily SSG combined with parommycin (PM)

ExcerptReferenceRelevance
" The present study was designed to assess the effectiveness of parenteral aminosidine, alone or combined with sodium stibogluconate, in visceral leishmaniasis, compared to treatment by stibogluconate alone."( Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.
Chunge, CN; Donno, L; Owate, J; Pamba, HO,
)
0.13
"Glycoside antibiotics including the macrolide antibiotics azithromycin, clarithromycin, and erythromycin and the aminoglycoside paromomycin were administered alone or combined with doxycycline, minocycline, or tetracycline to neonatal BALB/c mice experimentally infected with Cryptosporidium parvum."( Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice.
Ellis, W; Fayer, R, 1993
)
0.49
"BALB/c mice with an experimental visceral leishmaniasis produced by Leishmania infantum were treated with aminosidine sulphate alone or combined with meglumine antimoniate."( Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Derouin, F; Gangneux, JP; Garin, YJ; Sulahian, A, 1997
)
0.3
" The inhibitory effect was increased when the aminoglycoside paromomycin was combined with the PIs indinavir, ritonavir, and to a lesser extent saquinavir, compared to the PIs alone."( Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum.
Eichholz, J; Hommer, V; Petry, F, 2003
)
0.79
" Imiquimod (5-10 microg/ml) combined with either paromomycin (25, 50 and 100 microg/ml) or methylbenzethonium chloride (0."( Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
Bazarsky, E; El-On, J; Sneir, R, 2007
)
0.83
" In 2002, we replaced the standard regimen of 30 days of daily sodium stibogluconate (SSG) with a 17-day regimen of daily SSG combined with paromomycin (PM)."( Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
Collin, SM; Davidson, RN; Gatluak, F; Keus, K; Melaku, Y; Ritmeijer, K, 2007
)
0.76
"The aim of this 6-month, randomized, blinded, controlled clinical trial was to compare the efficacy and safety of aminosidine-allopurinol combination with that of meglumine antimoniate-allopurinol combination for the treatment of leishmaniosis in dogs without stage III or IV chronic kidney disease."( A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania inf
Apostolidis, K; Athanasiou, LV; Chatzis, MK; Ikonomopoulos, J; Kasabalis, D; Leontides, LS; Mataragka, A; Petanides, T; Saridomichelakis, MN; Xenoulis, PG, 2020
)
0.78

Bioavailability

Paromomycin, an oral, poorly absorbed aminoglycoside, is an alternate, potentially less toxic agent for treatment of symptomatic giardiasis in pregnancy. The aim of the present study was to determine whether mycotoxin-contaminated diets can alter the oral bioavailability of the antibiotics doxycycline and parommycin.

ExcerptReferenceRelevance
" Consequently, it was presumed that some acute effect, such as neuro-muscular toxicity, of the drug, which was well absorbed into parasite, but ill-absorbed from the gastrointestinal tract of human, is one of the mode of antihelminthic activity, in this case."( [A case of fish tape-worm infection treated with paromomycin and an observation on its mode of action. II. With special reference to aminosidine (author's transl)].
Kanazawa, Y, 1977
)
0.51
" Paromomycin, an oral, poorly absorbed aminoglycoside, is an alternate, potentially less toxic agent for treatment of symptomatic giardiasis in pregnancy."( Giardiasis in pregnancy.
Amstey, MS; Del Bene, VE; Kreutner, AK, 1981
)
1.17
" Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days in mice."( Novel arylimidamides for treatment of visceral leishmaniasis.
Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X, 2010
)
0.36
" It is the aim of the present study to determine whether mycotoxin-contaminated diets can alter the oral bioavailability of the antibiotics doxycycline and paromomycin in pigs, and whether a mycotoxin adsorbing agent included into diets interacts with those antibiotics."( Influence of mycotoxins and a mycotoxin adsorbing agent on the oral bioavailability of commonly used antibiotics in pigs.
Audenaert, K; Croubels, S; De Backer, P; De Baere, S; De Saeger, S; Devreese, M; Eeckhout, M; Goossens, J; Haesaert, G; Haesebrouck, F; Osselaere, A; Pasmans, F; Vandenbroucke, V; Verbrugghe, E, 2012
)
0.58
"Comparatively significant increase in oral plasma exposure of paromomycin was observed with an alternative oral formulation approach, use of P-gp and CYP inhibitors resulting in improved oral bioavailability up to 16%."( Investigation of
Gilhotra, RM; K Pinjari, MJS; Somani, R,
)
0.37

Dosage Studied

Parmomycin (PAR) has been suggested for the topical treatment of disease-related lesions. Even when formulated in high drug-loading dosage forms, presents controversial efficacy. Toxicoses were attributed to a combination of an excessive dosage of paromomycin and absorption of the drug across injured intestinal mucosal epithelium.

ExcerptRelevanceReference
"Changes in the dosage of genes encoding elongation factor EF-1 alpha were shown to cause parallel changes in the misreading of nonsense codons."( Elongation factor EF-1 alpha gene dosage alters translational fidelity in Saccharomyces cerevisiae.
Firoozan, M; Grant, CM; Liebman, S; Picologlou, S; Song, JM; Tuite, MF, 1989
)
0.28
" Rifaximin proved to be active on both aerobic and anaerobic bacteria and is thus effective, even at the dosage used, in the treatment of HE."( A non-absorbable rifamycin for treatment of hepatic encephalopathy.
Celle, G; De Leo, C; Eftimiadi, C; Rovida, S; Schito, GC; Sukkar, GS; Testa, R, 1985
)
0.27
" nana were eliminated from mice by bithionol and mebendazole respectively, at the same dosage regimen."( Anthelmintic effects of bithionol, paromomycin sulphate, flubendazole and mebendazole on mature and immature Hymenolepis nana in mice.
Maki, J; Yanagisawa, T, 1985
)
0.55
" The effects of 4 antibiotics orally administered in varying dosage schedules were studied."( Antibiotic therapy of cholera.
Greenough, WB; Islam, MR; Lindenbaum, J, 1967
)
0.25
" The trials suffered from unclear methods, variability in study populations and total dosage of medication used, inaccuracy in determining outcomes, and inadequate sample sizes."( Issues in clinical parasitology: the treatment of giardiasis.
Davidson, RA, 1984
)
0.27
" ditremum in vitro and in the dosage of 46--56 mg/kg in diphyllobothriasis lata patients."( [In vitro and in vivo effects of paromomycin sulfate on tapeworm, especially Diphyllobothrium ditremum, and clinical effects on diphyllobothriasis in man].
Kutsumi, H; Miyamoto, K; Nakao, M, 1983
)
0.55
"In the dexamethasone-treated rat model of cryptosporidiosis, paromomycin was effective at a dosage of 50 mg/kg/day or more for ileal infection and 200 mg/kg/day or more for cecal infection."( Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model.
Carbon, C; Garry, L; Gaudebout, C; Marche, C; Pocidalo, JJ; Polianski, J; Verdon, R, 1995
)
0.81
"The kinetic behaviour of the aminoglycoside aminosidine, given at 15 mg/kg intravenously, intramuscularly and subcutaneously, was studied in 5 dogs to determine the appropriate dosage schedule."( Pharmacokinetics and dosing regimen of aminosidine in the dog.
Belloli, C; Carelli, G; Carli, S; Crescenzo, G; Ormas, P; Sonzogni, O; Villa, R, 1996
)
0.29
" This dosage was reduced to 200 mg/day for patients below 12 years of age."( A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey.
Baydar, I; Ozgoztasi, O, 1997
)
0.57
" Toxicoses were attributed to a combination of an excessive dosage of paromomycin and absorption of the drug across injured intestinal mucosal epithelium."( Acute renal failure in four cats treated with paromomycin.
Gilger, BC; Gookin, JL; Papich, MG; Riviere, JE, 1999
)
0.8
" The exact dosage still has to be determined."( Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin.
Poppe, WA, 2001
)
0.55
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" The developed method was applied to estimate PM quantitatively in two parenteral dosage forms."( Characterization, thermal stability studies, and analytical method development of Paromomycin for formulation development.
Khan, W; Kumar, N, 2011
)
0.59
" A clear dose-response effect was found for paromomycin."( Assessment of the antihistomonal effect of paromomycin and tiamulin.
De Gussem, K; Landman, WJ; van der Heijden, HM, 2011
)
0.89
" These drugs were incorporated in conventional dosage forms or loaded in lipid nanocarries, which have been used mainly for improved skin delivery and antileishmanial activity."( Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA, 2012
)
0.38
" Insights into the most promising delivery strategies to improve treatment of CL with PA and AmB using conventional dosage forms, lipid nanocarriers, and combined therapy are presented and discussed."( Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA, 2012
)
0.38
" The aim of this study was to evaluate the efficacy of an optimized dosage regimen of aminosidine for the treatment of canine leishmaniosis (CanL) in terms of clinical remission, restoration of clinicopathological abnormalities, evolution of antibody titer, lymph node and bone marrow parasitic density and of PCR-based parasitological cure."( Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial.
Athanasiou, LV; Kontos, VI; Rallis, TS; Saridomichelakis, MN; Spanakos, G, 2013
)
0.39
" We advanced from a one-compartmental design of the stomach to a much more appropriate, multi-compartmental 'mixing tank' gastric model that reflects drug distribution along the different regions of the stomach as a consequence of randomly dosing relative to the different contractile phases of the migrating motor complex (MMC)."( Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach.
Amidon, GE; Amidon, GL; Baker, JR; Benninghoff, G; Bermejo, M; Dickens, J; Fan, J; Frances, A; Hasler, WL; Hens, B; Koenigsknecht, MJ; Lee, A; Lionberger, R; Löbenberg, R; Paixão, P; Salehi, N; Shedden, K; Sun, D; Talattof, A; Tsume, Y; Wen, B; Wysocki, J; Yu, A, 2018
)
0.71
" Allometric dosing ensured similar MF exposure in children (<12 years) and adults."( Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Alcoba, G; Alvar, J; Alves, F; Dorlo, TPC; Egondi, T; Fikre, H; Ismail Omer Haroun, A; Khalil, EAG; Mbui, J; Mekonnen, T; Mersha, D; Mohammed, R; Musa Younis, B; Musa, AM; Muthoni Ouattara, G; Nakanwagi, P; Njenga, S; Nour, A; Olobo, J; Omollo, T; Ritmeijer, K; Sagaki, P; Sisay, K; Solomos, A; Taha Ahmed Elmukashfi, E; Verrest, L; Wasunna, M, 2023
)
2.35
"To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated."( Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M, 2023
)
1.36
" Paromomycin (PAR), an aminoglycoside antibiotic, has been suggested for the topical treatment of disease-related lesions, but even when formulated in high drug-loading dosage forms, presents controversial efficacy."( Enhanced topical paromomycin delivery for cutaneous leishmaniasis treatment: Passive and iontophoretic approaches.
Andrade, JFM; Cunha-Filho, M; de Sá, FAP; Gelfuso, GM; Gratieri, T; Kalia, YN; Lapteva, M; Miranda, TC, 2023
)
2.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
antiprotozoal drugAny antimicrobial drug which is used to treat or prevent protozoal infections.
anthelminthic drugSubstance intended to kill parasitic worms (helminths).
antiparasitic agentA substance used to treat or prevent parasitic infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminoglycoside antibiotic
amino cyclitol glycoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Paromomycin Action Pathway14

Protein Targets (57)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
30S ribosomal protein S6Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S7Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L15Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L10Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L11Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L7/L12Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L19Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L1Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L20Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L27Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L28Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L29Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L31Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L31 type BEscherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L32Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L33Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L34Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L35Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L36Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S10Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S11Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S12Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S13Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S16Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S18Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S19Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S20Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S2Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S3Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S4Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S5Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S8Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S9Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L13Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L14Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L16Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L23Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S15Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L17Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L21Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L30Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L6Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S14Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S17Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S1Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L18Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L2Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L3Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L24Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L4Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L22Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L5Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
30S ribosomal protein S21Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L25Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
50S ribosomal protein L36 2Escherichia coli K-12IC50 (µMol)0.03550.00891.20355.0000AID1575870; AID1881656
Tyrosyl-DNA phosphodiesterase 1Homo sapiens (human)IC50 (µMol)21,000.00000.01203.32138.4300AID1631084
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (62)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cytoplasmic translation30S ribosomal protein S6Escherichia coli K-12
translation30S ribosomal protein S6Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S7Escherichia coli K-12
negative regulation of translation30S ribosomal protein S7Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S7Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S7Escherichia coli K-12
translation30S ribosomal protein S7Escherichia coli K-12
negative regulation of translation30S ribosomal protein S7Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L15Escherichia coli K-12
translation50S ribosomal protein L15Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L10Escherichia coli K-12
translation50S ribosomal protein L10Escherichia coli K-12
regulation of translation50S ribosomal protein L10Escherichia coli K-12
negative regulation of translation50S ribosomal protein L10Escherichia coli K-12
translation50S ribosomal protein L11Escherichia coli K-12
translational termination50S ribosomal protein L11Escherichia coli K-12
stringent response50S ribosomal protein L11Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L11Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L11Escherichia coli K-12
translation50S ribosomal protein L11Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L7/L12Escherichia coli K-12
translation50S ribosomal protein L7/L12Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L19Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L19Escherichia coli K-12
translation50S ribosomal protein L19Escherichia coli K-12
negative regulation of translational initiation50S ribosomal protein L1Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L1Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L1Escherichia coli K-12
translation50S ribosomal protein L1Escherichia coli K-12
regulation of translation50S ribosomal protein L1Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L20Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L20Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L20Escherichia coli K-12
translation50S ribosomal protein L20Escherichia coli K-12
negative regulation of translation50S ribosomal protein L20Escherichia coli K-12
cytosolic ribosome assembly50S ribosomal protein L27Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L27Escherichia coli K-12
regulation of cell growth50S ribosomal protein L27Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L27Escherichia coli K-12
translation50S ribosomal protein L27Escherichia coli K-12
positive regulation of ribosome biogenesis50S ribosomal protein L27Escherichia coli K-12
assembly of large subunit precursor of preribosome50S ribosomal protein L27Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L28Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L28Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L28Escherichia coli K-12
translation50S ribosomal protein L28Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L29Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L29Escherichia coli K-12
translation50S ribosomal protein L29Escherichia coli K-12
translation50S ribosomal protein L31Escherichia coli K-12
translational initiation50S ribosomal protein L31Escherichia coli K-12
negative regulation of cytoplasmic translational initiation50S ribosomal protein L31Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L31Escherichia coli K-12
translation50S ribosomal protein L31Escherichia coli K-12
cellular response to zinc ion starvation50S ribosomal protein L31 type BEscherichia coli K-12
cytoplasmic translation50S ribosomal protein L31 type BEscherichia coli K-12
translation50S ribosomal protein L31 type BEscherichia coli K-12
response to reactive oxygen species50S ribosomal protein L32Escherichia coli K-12
response to radiation50S ribosomal protein L32Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L32Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L32Escherichia coli K-12
translation50S ribosomal protein L32Escherichia coli K-12
response to antibiotic50S ribosomal protein L33Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L33Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L33Escherichia coli K-12
translation50S ribosomal protein L33Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L34Escherichia coli K-12
translation50S ribosomal protein L34Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L35Escherichia coli K-12
translation50S ribosomal protein L35Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L36Escherichia coli K-12
translation50S ribosomal protein L36Escherichia coli K-12
transcription antitermination30S ribosomal protein S10Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S10Escherichia coli K-12
translation30S ribosomal protein S10Escherichia coli K-12
transcription antitermination30S ribosomal protein S10Escherichia coli K-12
regulation of DNA-templated transcription elongation30S ribosomal protein S10Escherichia coli K-12
ribosome biogenesis30S ribosomal protein S10Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S11Escherichia coli K-12
translation30S ribosomal protein S11Escherichia coli K-12
Group I intron splicing30S ribosomal protein S12Escherichia coli K-12
positive regulation of RNA splicing30S ribosomal protein S12Escherichia coli K-12
RNA folding30S ribosomal protein S12Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S12Escherichia coli K-12
translation30S ribosomal protein S12Escherichia coli K-12
response to antibiotic30S ribosomal protein S12Escherichia coli K-12
maintenance of translational fidelity30S ribosomal protein S12Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S13Escherichia coli K-12
translation30S ribosomal protein S13Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S16Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S16Escherichia coli K-12
DNA metabolic process30S ribosomal protein S16Escherichia coli K-12
translation30S ribosomal protein S16Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S18Escherichia coli K-12
translation30S ribosomal protein S18Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S19Escherichia coli K-12
translation30S ribosomal protein S19Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S19Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S20Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S20Escherichia coli K-12
translation30S ribosomal protein S20Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S2Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S2Escherichia coli K-12
translation30S ribosomal protein S2Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S3Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S3Escherichia coli K-12
translation30S ribosomal protein S3Escherichia coli K-12
transcription antitermination30S ribosomal protein S4Escherichia coli K-12
negative regulation of translational initiation30S ribosomal protein S4Escherichia coli K-12
maintenance of translational fidelity30S ribosomal protein S4Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S4Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S4Escherichia coli K-12
DNA-templated transcription termination30S ribosomal protein S4Escherichia coli K-12
translation30S ribosomal protein S4Escherichia coli K-12
regulation of translation30S ribosomal protein S4Escherichia coli K-12
transcription antitermination30S ribosomal protein S4Escherichia coli K-12
ribosome biogenesis30S ribosomal protein S4Escherichia coli K-12
response to antibiotic30S ribosomal protein S4Escherichia coli K-12
ribosomal small subunit biogenesis30S ribosomal protein S4Escherichia coli K-12
maintenance of translational fidelity30S ribosomal protein S5Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S5Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S5Escherichia coli K-12
translation30S ribosomal protein S5Escherichia coli K-12
response to antibiotic30S ribosomal protein S5Escherichia coli K-12
regulation of mRNA stability30S ribosomal protein S8Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S8Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S8Escherichia coli K-12
translation30S ribosomal protein S8Escherichia coli K-12
regulation of translation30S ribosomal protein S8Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S9Escherichia coli K-12
translation30S ribosomal protein S9Escherichia coli K-12
negative regulation of translation50S ribosomal protein L13Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L13Escherichia coli K-12
translation50S ribosomal protein L13Escherichia coli K-12
negative regulation of translation50S ribosomal protein L13Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L14Escherichia coli K-12
translation50S ribosomal protein L14Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L16Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L16Escherichia coli K-12
translation50S ribosomal protein L16Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L23Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L23Escherichia coli K-12
translation50S ribosomal protein L23Escherichia coli K-12
translation30S ribosomal protein S15Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S15Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S15Escherichia coli K-12
translation30S ribosomal protein S15Escherichia coli K-12
regulation of translation30S ribosomal protein S15Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L17Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L17Escherichia coli K-12
translation50S ribosomal protein L17Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L21Escherichia coli K-12
translation50S ribosomal protein L21Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L30Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L30Escherichia coli K-12
translation50S ribosomal protein L30Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L6Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L6Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L6Escherichia coli K-12
translation50S ribosomal protein L6Escherichia coli K-12
response to antibiotic50S ribosomal protein L6Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S14Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S14Escherichia coli K-12
translation30S ribosomal protein S14Escherichia coli K-12
response to antibiotic30S ribosomal protein S17Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S17Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S17Escherichia coli K-12
translation30S ribosomal protein S17Escherichia coli K-12
response to antibiotic30S ribosomal protein S17Escherichia coli K-12
translation30S ribosomal protein S1Escherichia coli K-12
RNA secondary structure unwinding30S ribosomal protein S1Escherichia coli K-12
negative regulation of cytoplasmic translation30S ribosomal protein S1Escherichia coli K-12
positive regulation of cytoplasmic translation30S ribosomal protein S1Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S1Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S1Escherichia coli K-12
translation30S ribosomal protein S1Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L18Escherichia coli K-12
translation50S ribosomal protein L18Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L2Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L2Escherichia coli K-12
translation50S ribosomal protein L2Escherichia coli K-12
negative regulation of DNA-templated DNA replication initiation50S ribosomal protein L2Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L3Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L3Escherichia coli K-12
translation50S ribosomal protein L3Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L24Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L24Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L24Escherichia coli K-12
translation50S ribosomal protein L24Escherichia coli K-12
transcriptional attenuation50S ribosomal protein L4Escherichia coli K-12
negative regulation of cytoplasmic translation50S ribosomal protein L4Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L4Escherichia coli K-12
DNA-templated transcription termination50S ribosomal protein L4Escherichia coli K-12
translation50S ribosomal protein L4Escherichia coli K-12
regulation of translation50S ribosomal protein L4Escherichia coli K-12
negative regulation of translation50S ribosomal protein L4Escherichia coli K-12
ribosome assembly50S ribosomal protein L4Escherichia coli K-12
negative regulation of DNA-templated transcription50S ribosomal protein L4Escherichia coli K-12
response to antibiotic50S ribosomal protein L4Escherichia coli K-12
translation50S ribosomal protein L22Escherichia coli K-12
cytosolic ribosome assembly50S ribosomal protein L22Escherichia coli K-12
assembly of large subunit precursor of preribosome50S ribosomal protein L22Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L22Escherichia coli K-12
translation50S ribosomal protein L22Escherichia coli K-12
ribosome assembly50S ribosomal protein L22Escherichia coli K-12
response to antibiotic50S ribosomal protein L22Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L5Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L5Escherichia coli K-12
translation50S ribosomal protein L5Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S21Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S21Escherichia coli K-12
translation30S ribosomal protein S21Escherichia coli K-12
translation50S ribosomal protein L25Escherichia coli K-12
response to radiation50S ribosomal protein L25Escherichia coli K-12
negative regulation of translation50S ribosomal protein L25Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L25Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L25Escherichia coli K-12
translation50S ribosomal protein L25Escherichia coli K-12
translation50S ribosomal protein L36 2Escherichia coli K-12
single strand break repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
DNA repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
double-strand break repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
structural constituent of ribosome30S ribosomal protein S6Escherichia coli K-12
protein binding30S ribosomal protein S6Escherichia coli K-12
rRNA binding30S ribosomal protein S6Escherichia coli K-12
mRNA 5'-UTR binding30S ribosomal protein S6Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S6Escherichia coli K-12
tRNA binding30S ribosomal protein S7Escherichia coli K-12
RNA binding30S ribosomal protein S7Escherichia coli K-12
mRNA binding30S ribosomal protein S7Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S7Escherichia coli K-12
protein binding30S ribosomal protein S7Escherichia coli K-12
rRNA binding30S ribosomal protein S7Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L15Escherichia coli K-12
protein binding50S ribosomal protein L15Escherichia coli K-12
rRNA binding50S ribosomal protein L15Escherichia coli K-12
GTPase activity50S ribosomal protein L10Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L10Escherichia coli K-12
protein binding50S ribosomal protein L10Escherichia coli K-12
rRNA binding50S ribosomal protein L10Escherichia coli K-12
ribosome binding50S ribosomal protein L10Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L10Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L11Escherichia coli K-12
protein binding50S ribosomal protein L11Escherichia coli K-12
rRNA binding50S ribosomal protein L11Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L11Escherichia coli K-12
GTPase activity50S ribosomal protein L7/L12Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L7/L12Escherichia coli K-12
protein binding50S ribosomal protein L7/L12Escherichia coli K-12
protein homodimerization activity50S ribosomal protein L7/L12Escherichia coli K-12
ribosome binding50S ribosomal protein L7/L12Escherichia coli K-12
mRNA binding50S ribosomal protein L7/L12Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L19Escherichia coli K-12
rRNA binding50S ribosomal protein L19Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L19Escherichia coli K-12
tRNA binding50S ribosomal protein L1Escherichia coli K-12
RNA binding50S ribosomal protein L1Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L1Escherichia coli K-12
protein binding50S ribosomal protein L1Escherichia coli K-12
rRNA binding50S ribosomal protein L1Escherichia coli K-12
mRNA regulatory element binding translation repressor activity50S ribosomal protein L20Escherichia coli K-12
mRNA binding50S ribosomal protein L20Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L20Escherichia coli K-12
rRNA binding50S ribosomal protein L20Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L20Escherichia coli K-12
tRNA binding50S ribosomal protein L27Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L27Escherichia coli K-12
protein binding50S ribosomal protein L27Escherichia coli K-12
rRNA binding50S ribosomal protein L27Escherichia coli K-12
ribosome binding50S ribosomal protein L27Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L28Escherichia coli K-12
protein binding50S ribosomal protein L28Escherichia coli K-12
rRNA binding50S ribosomal protein L28Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L29Escherichia coli K-12
rRNA binding50S ribosomal protein L29Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L31Escherichia coli K-12
zinc ion binding50S ribosomal protein L31Escherichia coli K-12
rRNA binding50S ribosomal protein L31Escherichia coli K-12
metal ion binding50S ribosomal protein L31Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L31 type BEscherichia coli K-12
structural constituent of ribosome50S ribosomal protein L32Escherichia coli K-12
protein binding50S ribosomal protein L32Escherichia coli K-12
tRNA binding50S ribosomal protein L33Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L33Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L34Escherichia coli K-12
protein binding50S ribosomal protein L34Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L35Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L36Escherichia coli K-12
tRNA binding30S ribosomal protein S10Escherichia coli K-12
transcription antitermination factor activity, RNA binding30S ribosomal protein S10Escherichia coli K-12
RNA binding30S ribosomal protein S10Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S10Escherichia coli K-12
protein binding30S ribosomal protein S10Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S11Escherichia coli K-12
protein binding30S ribosomal protein S11Escherichia coli K-12
rRNA binding30S ribosomal protein S11Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S11Escherichia coli K-12
tRNA binding30S ribosomal protein S12Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S12Escherichia coli K-12
protein binding30S ribosomal protein S12Escherichia coli K-12
rRNA binding30S ribosomal protein S12Escherichia coli K-12
misfolded RNA binding30S ribosomal protein S12Escherichia coli K-12
tRNA binding30S ribosomal protein S13Escherichia coli K-12
RNA binding30S ribosomal protein S13Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S13Escherichia coli K-12
protein binding30S ribosomal protein S13Escherichia coli K-12
rRNA binding30S ribosomal protein S13Escherichia coli K-12
four-way junction DNA binding30S ribosomal protein S16Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S16Escherichia coli K-12
endonuclease activity30S ribosomal protein S16Escherichia coli K-12
DNA endonuclease activity30S ribosomal protein S16Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S18Escherichia coli K-12
protein binding30S ribosomal protein S18Escherichia coli K-12
rRNA binding30S ribosomal protein S18Escherichia coli K-12
mRNA 5'-UTR binding30S ribosomal protein S18Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S18Escherichia coli K-12
tRNA binding30S ribosomal protein S19Escherichia coli K-12
RNA binding30S ribosomal protein S19Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S19Escherichia coli K-12
rRNA binding30S ribosomal protein S19Escherichia coli K-12
RNA binding30S ribosomal protein S20Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S20Escherichia coli K-12
ornithine decarboxylase inhibitor activity30S ribosomal protein S20Escherichia coli K-12
rRNA binding30S ribosomal protein S20Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S20Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S2Escherichia coli K-12
protein binding30S ribosomal protein S2Escherichia coli K-12
zinc ion binding30S ribosomal protein S2Escherichia coli K-12
RNA binding30S ribosomal protein S3Escherichia coli K-12
mRNA binding30S ribosomal protein S3Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S3Escherichia coli K-12
rRNA binding30S ribosomal protein S3Escherichia coli K-12
mRNA regulatory element binding translation repressor activity30S ribosomal protein S4Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S4Escherichia coli K-12
protein binding30S ribosomal protein S4Escherichia coli K-12
rRNA binding30S ribosomal protein S4Escherichia coli K-12
mRNA 5'-UTR binding30S ribosomal protein S4Escherichia coli K-12
RNA binding30S ribosomal protein S5Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S5Escherichia coli K-12
protein binding30S ribosomal protein S5Escherichia coli K-12
rRNA binding30S ribosomal protein S5Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S8Escherichia coli K-12
rRNA binding30S ribosomal protein S8Escherichia coli K-12
tRNA binding30S ribosomal protein S9Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S9Escherichia coli K-12
RNA binding30S ribosomal protein S9Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L13Escherichia coli K-12
zinc ion binding50S ribosomal protein L13Escherichia coli K-12
mRNA 5'-UTR binding50S ribosomal protein L13Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L13Escherichia coli K-12
mRNA binding50S ribosomal protein L13Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L14Escherichia coli K-12
protein binding50S ribosomal protein L14Escherichia coli K-12
rRNA binding50S ribosomal protein L14Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L14Escherichia coli K-12
tRNA binding50S ribosomal protein L16Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L16Escherichia coli K-12
rRNA binding50S ribosomal protein L16Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L23Escherichia coli K-12
protein binding50S ribosomal protein L23Escherichia coli K-12
rRNA binding50S ribosomal protein L23Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S15Escherichia coli K-12
rRNA binding30S ribosomal protein S15Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S15Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L17Escherichia coli K-12
protein binding50S ribosomal protein L17Escherichia coli K-12
RNA binding50S ribosomal protein L21Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L21Escherichia coli K-12
rRNA binding50S ribosomal protein L21Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L30Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L6Escherichia coli K-12
rRNA binding50S ribosomal protein L6Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L6Escherichia coli K-12
tRNA binding30S ribosomal protein S14Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S14Escherichia coli K-12
rRNA binding30S ribosomal protein S14Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S17Escherichia coli K-12
zinc ion binding30S ribosomal protein S17Escherichia coli K-12
rRNA binding30S ribosomal protein S17Escherichia coli K-12
molecular adaptor activity30S ribosomal protein S17Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S17Escherichia coli K-12
RNA binding30S ribosomal protein S1Escherichia coli K-12
single-stranded RNA binding30S ribosomal protein S1Escherichia coli K-12
mRNA binding30S ribosomal protein S1Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S1Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L18Escherichia coli K-12
5S rRNA binding50S ribosomal protein L18Escherichia coli K-12
rRNA binding50S ribosomal protein L18Escherichia coli K-12
RNA binding50S ribosomal protein L2Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L2Escherichia coli K-12
protein binding50S ribosomal protein L2Escherichia coli K-12
zinc ion binding50S ribosomal protein L2Escherichia coli K-12
transferase activity50S ribosomal protein L2Escherichia coli K-12
rRNA binding50S ribosomal protein L2Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L3Escherichia coli K-12
protein binding50S ribosomal protein L3Escherichia coli K-12
rRNA binding50S ribosomal protein L3Escherichia coli K-12
RNA binding50S ribosomal protein L24Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L24Escherichia coli K-12
protein binding50S ribosomal protein L24Escherichia coli K-12
rRNA binding50S ribosomal protein L24Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L24Escherichia coli K-12
RNA-binding transcription regulator activity50S ribosomal protein L4Escherichia coli K-12
DNA binding50S ribosomal protein L4Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L4Escherichia coli K-12
protein binding50S ribosomal protein L4Escherichia coli K-12
rRNA binding50S ribosomal protein L4Escherichia coli K-12
translation repressor activity50S ribosomal protein L4Escherichia coli K-12
mRNA 5'-UTR binding50S ribosomal protein L4Escherichia coli K-12
endoribonuclease inhibitor activity50S ribosomal protein L4Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L22Escherichia coli K-12
protein binding50S ribosomal protein L22Escherichia coli K-12
rRNA binding50S ribosomal protein L22Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L22Escherichia coli K-12
tRNA binding50S ribosomal protein L5Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L5Escherichia coli K-12
5S rRNA binding50S ribosomal protein L5Escherichia coli K-12
rRNA binding50S ribosomal protein L5Escherichia coli K-12
RNA binding50S ribosomal protein L5Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S21Escherichia coli K-12
rRNA binding30S ribosomal protein S21Escherichia coli K-12
RNA binding50S ribosomal protein L25Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L25Escherichia coli K-12
5S rRNA binding50S ribosomal protein L25Escherichia coli K-12
rRNA binding50S ribosomal protein L25Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L36 2Escherichia coli K-12
double-stranded DNA bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
single-stranded DNA bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
exonuclease activityTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
protein bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
3'-tyrosyl-DNA phosphodiesterase activityTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasm30S ribosomal protein S6Escherichia coli K-12
cytosol30S ribosomal protein S6Escherichia coli K-12
ribosome30S ribosomal protein S6Escherichia coli K-12
intracellular organelle30S ribosomal protein S6Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S6Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S6Escherichia coli K-12
cytosol30S ribosomal protein S7Escherichia coli K-12
ribosome30S ribosomal protein S7Escherichia coli K-12
membrane30S ribosomal protein S7Escherichia coli K-12
cytoplasm30S ribosomal protein S7Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S7Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S7Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S7Escherichia coli K-12
ribosome30S ribosomal protein S7Escherichia coli K-12
ribosome50S ribosomal protein L15Escherichia coli K-12
cytoplasm50S ribosomal protein L15Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L15Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L15Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L15Escherichia coli K-12
cytosol50S ribosomal protein L10Escherichia coli K-12
ribosome50S ribosomal protein L10Escherichia coli K-12
cytoplasm50S ribosomal protein L10Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L10Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L10Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L10Escherichia coli K-12
cytosol50S ribosomal protein L11Escherichia coli K-12
ribosome50S ribosomal protein L11Escherichia coli K-12
cytoplasm50S ribosomal protein L11Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L11Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L11Escherichia coli K-12
cytoplasm50S ribosomal protein L7/L12Escherichia coli K-12
cytosol50S ribosomal protein L7/L12Escherichia coli K-12
ribosome50S ribosomal protein L7/L12Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L7/L12Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L7/L12Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L7/L12Escherichia coli K-12
cytosol50S ribosomal protein L19Escherichia coli K-12
ribosome50S ribosomal protein L19Escherichia coli K-12
cytoplasm50S ribosomal protein L19Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L19Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L19Escherichia coli K-12
cytosol50S ribosomal protein L1Escherichia coli K-12
ribosome50S ribosomal protein L1Escherichia coli K-12
cytoplasm50S ribosomal protein L1Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L1Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L1Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L1Escherichia coli K-12
cytosol50S ribosomal protein L20Escherichia coli K-12
ribosome50S ribosomal protein L20Escherichia coli K-12
cytoplasm50S ribosomal protein L20Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L20Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L20Escherichia coli K-12
ribosome50S ribosomal protein L27Escherichia coli K-12
cytoplasm50S ribosomal protein L27Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L27Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L27Escherichia coli K-12
cytosol50S ribosomal protein L28Escherichia coli K-12
ribosome50S ribosomal protein L28Escherichia coli K-12
cytoplasm50S ribosomal protein L28Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L28Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L28Escherichia coli K-12
ribosome50S ribosomal protein L29Escherichia coli K-12
cytoplasm50S ribosomal protein L29Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L29Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L29Escherichia coli K-12
cytosol50S ribosomal protein L31Escherichia coli K-12
ribosome50S ribosomal protein L31Escherichia coli K-12
cytoplasm50S ribosomal protein L31Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L31Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L31Escherichia coli K-12
ribosome50S ribosomal protein L31 type BEscherichia coli K-12
cytoplasm50S ribosomal protein L31 type BEscherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L31 type BEscherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L31 type BEscherichia coli K-12
cytosol50S ribosomal protein L32Escherichia coli K-12
ribosome50S ribosomal protein L32Escherichia coli K-12
cytoplasm50S ribosomal protein L32Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L32Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L32Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L32Escherichia coli K-12
cytoplasm50S ribosomal protein L33Escherichia coli K-12
cytosol50S ribosomal protein L33Escherichia coli K-12
ribosome50S ribosomal protein L33Escherichia coli K-12
intracellular organelle50S ribosomal protein L33Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L33Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L33Escherichia coli K-12
ribosome50S ribosomal protein L34Escherichia coli K-12
cytoplasm50S ribosomal protein L34Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L34Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L34Escherichia coli K-12
ribosome50S ribosomal protein L35Escherichia coli K-12
cytoplasm50S ribosomal protein L35Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L35Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L35Escherichia coli K-12
cytoplasm50S ribosomal protein L36Escherichia coli K-12
ribosome50S ribosomal protein L36Escherichia coli K-12
intracellular organelle50S ribosomal protein L36Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L36Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L36Escherichia coli K-12
cytosol30S ribosomal protein S10Escherichia coli K-12
ribosome30S ribosomal protein S10Escherichia coli K-12
cytoplasm30S ribosomal protein S10Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S10Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S10Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S10Escherichia coli K-12
cytosol30S ribosomal protein S11Escherichia coli K-12
ribosome30S ribosomal protein S11Escherichia coli K-12
cytoplasm30S ribosomal protein S11Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S11Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S11Escherichia coli K-12
cytosol30S ribosomal protein S12Escherichia coli K-12
ribosome30S ribosomal protein S12Escherichia coli K-12
cytoplasm30S ribosomal protein S12Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S12Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S12Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S12Escherichia coli K-12
ribosome30S ribosomal protein S12Escherichia coli K-12
cytosol30S ribosomal protein S13Escherichia coli K-12
ribosome30S ribosomal protein S13Escherichia coli K-12
cytoplasm30S ribosomal protein S13Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S13Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S13Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S13Escherichia coli K-12
cytosol30S ribosomal protein S13Escherichia coli K-12
cytoplasm30S ribosomal protein S16Escherichia coli K-12
ribosome30S ribosomal protein S16Escherichia coli K-12
intracellular organelle30S ribosomal protein S16Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S16Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S16Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S16Escherichia coli K-12
cytosol30S ribosomal protein S18Escherichia coli K-12
ribosome30S ribosomal protein S18Escherichia coli K-12
cytoplasm30S ribosomal protein S18Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S18Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S18Escherichia coli K-12
cytoplasm30S ribosomal protein S19Escherichia coli K-12
cytosol30S ribosomal protein S19Escherichia coli K-12
ribosome30S ribosomal protein S19Escherichia coli K-12
intracellular organelle30S ribosomal protein S19Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S19Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S19Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S19Escherichia coli K-12
cytosol30S ribosomal protein S20Escherichia coli K-12
ribosome30S ribosomal protein S20Escherichia coli K-12
cytoplasm30S ribosomal protein S20Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S20Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S20Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S20Escherichia coli K-12
cytosol30S ribosomal protein S20Escherichia coli K-12
ribosome30S ribosomal protein S2Escherichia coli K-12
cytoplasm30S ribosomal protein S2Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S2Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S2Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S2Escherichia coli K-12
cytosol30S ribosomal protein S3Escherichia coli K-12
ribosome30S ribosomal protein S3Escherichia coli K-12
cytoplasm30S ribosomal protein S3Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S3Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S3Escherichia coli K-12
cytosol30S ribosomal protein S4Escherichia coli K-12
ribosome30S ribosomal protein S4Escherichia coli K-12
cytoplasm30S ribosomal protein S4Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S4Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S4Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S4Escherichia coli K-12
cytoplasm30S ribosomal protein S5Escherichia coli K-12
cytosol30S ribosomal protein S5Escherichia coli K-12
ribosome30S ribosomal protein S5Escherichia coli K-12
intracellular organelle30S ribosomal protein S5Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S5Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S5Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S5Escherichia coli K-12
cytoplasm30S ribosomal protein S8Escherichia coli K-12
cytosol30S ribosomal protein S8Escherichia coli K-12
ribosome30S ribosomal protein S8Escherichia coli K-12
intracellular organelle30S ribosomal protein S8Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S8Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S8Escherichia coli K-12
cytosol30S ribosomal protein S9Escherichia coli K-12
ribosome30S ribosomal protein S9Escherichia coli K-12
intracellular organelle30S ribosomal protein S9Escherichia coli K-12
cytoplasm30S ribosomal protein S9Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S9Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S9Escherichia coli K-12
cytoplasm50S ribosomal protein L13Escherichia coli K-12
cytosol50S ribosomal protein L13Escherichia coli K-12
ribosome50S ribosomal protein L13Escherichia coli K-12
intracellular organelle50S ribosomal protein L13Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L13Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L13Escherichia coli K-12
ribosome50S ribosomal protein L13Escherichia coli K-12
cytosol50S ribosomal protein L14Escherichia coli K-12
ribosome50S ribosomal protein L14Escherichia coli K-12
cytoplasm50S ribosomal protein L14Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L14Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L14Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L14Escherichia coli K-12
ribosome50S ribosomal protein L16Escherichia coli K-12
cytoplasm50S ribosomal protein L16Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L16Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L16Escherichia coli K-12
ribosome50S ribosomal protein L23Escherichia coli K-12
cytoplasm50S ribosomal protein L23Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L23Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L23Escherichia coli K-12
cytoplasm30S ribosomal protein S15Escherichia coli K-12
cytosol30S ribosomal protein S15Escherichia coli K-12
ribosome30S ribosomal protein S15Escherichia coli K-12
intracellular organelle30S ribosomal protein S15Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S15Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S15Escherichia coli K-12
cytosol50S ribosomal protein L17Escherichia coli K-12
ribosome50S ribosomal protein L17Escherichia coli K-12
cytoplasm50S ribosomal protein L17Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L17Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L17Escherichia coli K-12
cytoplasm50S ribosomal protein L21Escherichia coli K-12
cytosol50S ribosomal protein L21Escherichia coli K-12
ribosome50S ribosomal protein L21Escherichia coli K-12
intracellular organelle50S ribosomal protein L21Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L21Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L21Escherichia coli K-12
ribosome50S ribosomal protein L30Escherichia coli K-12
cytoplasm50S ribosomal protein L30Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L30Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L30Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L30Escherichia coli K-12
cytosol50S ribosomal protein L6Escherichia coli K-12
ribosome50S ribosomal protein L6Escherichia coli K-12
cytoplasm50S ribosomal protein L6Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L6Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L6Escherichia coli K-12
cytoplasm30S ribosomal protein S14Escherichia coli K-12
ribosome30S ribosomal protein S14Escherichia coli K-12
intracellular organelle30S ribosomal protein S14Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S14Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S14Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S14Escherichia coli K-12
ribosome30S ribosomal protein S17Escherichia coli K-12
cytoplasm30S ribosomal protein S17Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S17Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S17Escherichia coli K-12
cytoplasm30S ribosomal protein S1Escherichia coli K-12
ribosome30S ribosomal protein S1Escherichia coli K-12
membrane30S ribosomal protein S1Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S1Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S1Escherichia coli K-12
cytoplasm50S ribosomal protein L18Escherichia coli K-12
cytosol50S ribosomal protein L18Escherichia coli K-12
ribosome50S ribosomal protein L18Escherichia coli K-12
intracellular organelle50S ribosomal protein L18Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L18Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L18Escherichia coli K-12
cytosol50S ribosomal protein L2Escherichia coli K-12
ribosome50S ribosomal protein L2Escherichia coli K-12
cytoplasm50S ribosomal protein L2Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L2Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L2Escherichia coli K-12
DnaA-L2 complex50S ribosomal protein L2Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L2Escherichia coli K-12
cytosol50S ribosomal protein L3Escherichia coli K-12
ribosome50S ribosomal protein L3Escherichia coli K-12
cytoplasm50S ribosomal protein L3Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L3Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L3Escherichia coli K-12
cytosol50S ribosomal protein L24Escherichia coli K-12
ribosome50S ribosomal protein L24Escherichia coli K-12
cytoplasm50S ribosomal protein L24Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L24Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L24Escherichia coli K-12
cytosol50S ribosomal protein L4Escherichia coli K-12
ribosome50S ribosomal protein L4Escherichia coli K-12
cytoplasm50S ribosomal protein L4Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L4Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L4Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L4Escherichia coli K-12
cytosol50S ribosomal protein L22Escherichia coli K-12
ribosome50S ribosomal protein L22Escherichia coli K-12
cytoplasm50S ribosomal protein L22Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L22Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L22Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L22Escherichia coli K-12
cytosol50S ribosomal protein L5Escherichia coli K-12
ribosome50S ribosomal protein L5Escherichia coli K-12
cytoplasm50S ribosomal protein L5Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L5Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L5Escherichia coli K-12
cytosol30S ribosomal protein S21Escherichia coli K-12
ribosome30S ribosomal protein S21Escherichia coli K-12
cytoplasm30S ribosomal protein S21Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S21Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S21Escherichia coli K-12
cytosol50S ribosomal protein L25Escherichia coli K-12
ribosome50S ribosomal protein L25Escherichia coli K-12
cytoplasm50S ribosomal protein L25Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L25Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L25Escherichia coli K-12
ribosome50S ribosomal protein L36 2Escherichia coli K-12
cytosolic ribosome50S ribosomal protein L36 2Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L36 2Escherichia coli K-12
nucleoplasmTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
cytoplasmTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
plasma membraneTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
intracellular membrane-bounded organelleTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
nucleusTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (302)

Assay IDTitleYearJournalArticle
AID1468958Antileishmanial activity against Leishmania donovani MHOM/IN/80/DD8 amastigotes expressing Luc gene infected in mouse J774A.1 cells after 3 to 5 days by luciferase reporter gene assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID254255Dissociation constant against 16S rRNA A-site2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
The synthesis and 16S A-site rRNA recognition of carbohydrate-free aminoglycosides.
AID307261Ratio of Kcat/Km of bacterial APH(3')-3a kinase-mediated high affinity phosphorylation2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
6-hydroxy to 6'''-amino tethered ring-to-ring macrocyclic aminoglycosides as probes for APH(3')-IIIa kinase.
AID752501Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as cell surface wrinkling at 1 ug/mL after 1 hr by scanning electron microscopic analysis2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID212903Inhibition of human telomerase before assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID351920Suppression of Dystrophin R3381X nonsense mutant cDNA translation in TNT rabbit reticulocyte lysate transcription translation system at 25 to 100 uM at 30 degC after 90 mins by luciferase reporter gene assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID307259Activity of bacterial APH(3')-3a kinase assessed high affinity phosphorylation2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
6-hydroxy to 6'''-amino tethered ring-to-ring macrocyclic aminoglycosides as probes for APH(3')-IIIa kinase.
AID586924Antileishmanial activity against tafenoquine-resistant promastigotes of Leishmania major R4 assessed as inhibition of parasite growth after 72 hrs by MTT assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID1275220Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by Neubauer counting chamber analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Inhibitory effect of phenothiazine- and phenoxazine-derived chloroacetamides on Leishmania major growth and Trypanosoma brucei trypanothione reductase.
AID1275219Antileishmanial activity against promastigote stage of Leishmania major assessed as inhibition of parasite proliferation after 48 hrs by Alamar Blue assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Inhibitory effect of phenothiazine- and phenoxazine-derived chloroacetamides on Leishmania major growth and Trypanosoma brucei trypanothione reductase.
AID1241207Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID579904Antileishmanial activity against Leishmania donovani infected in Hamster assessed as inhibition of parasites growth at 50 mg/kg, ip for 5 times2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents.
AID752508Antibacterial activity against Streptococcus pyogenes serotype T5 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID278535Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium bifidum R0071 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID572375Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in trophozoites in colon at 100 mg/kg/day, po for 6 days by hematoxylin and eosin staining2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1569828Antileishmanial activity against promastigote stage of Leishmania infantum MHOM/TN/80/IPT1 assessed as reduction in parasite viability measured after 72 hrs by MTT assay2019European journal of medicinal chemistry, Oct-15, Volume: 1804-Aminoquinoline-based compounds as antileishmanial agents that inhibit the energy metabolism of Leishmania.
AID212742Inhibition of purified telomerase of Euplotes aediculatus at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID586925Antileishmanial activity against wild type promastigotes of Leishmania major MHOM/JL/80/Friedlin assessed as inhibition of parasite growth after 72 hrs by MTT assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID572374Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in trophozoites in appendix at 100 mg/kg/day, po for 6 days by hematoxylin and eosin staining2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID278556Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium pseudolongum ATCC 25562 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID540933Binding affinity to Streptomyces coelicolor 1147 30S ribosomal protein S12 assessed as inhibition of protein synthesis at 0.2 ug/ml by fluorescence assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID126450Dissociation constant for binding to mitochondrial 12S rRNA construct M3 was determined2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Decoding region bubble size and aminoglycoside antibiotic binding.
AID69924Antibacterial activity determined against Escherichia coli2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
2-piperidin-4-yl-benzimidazoles with broad spectrum antibacterial activities.
AID1468968Antileishmanial activity against Leishmania infantum isolate L3034 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID166715Tested for binding affinity against RNA construct C2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID1468974Antileishmanial activity against Leishmania mexicana MNYC/BZ/62/M379 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID752515Antibacterial activity against Streptococcus pyogenes serotype M1T1 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID752517Antibacterial activity against Staphylococcus aureus Cowan ATCC 12598 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID278524Antimicrobial activity against Bifidobacterium bifidum BB122007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278536Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium bifidum BB12 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1468962Antileishmanial activity against miltefosine resistant Leishmania infantum MHOM/FR/96/LEM3323 C14 MIL4 amastigotes infected in mouse primary peritoneal macrophages after 5 days by Giemsa staining based microscopic method2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID664696Antimicrobial activity against Staphylococcus aureus ATCC 292132011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID278567Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium thermophilum ATCC 25866 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID255895Inhibitory concentration against cell-free bacterial transcription / translation (T/T) assay2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
The synthesis and 16S A-site rRNA recognition of carbohydrate-free aminoglycosides.
AID428871Antibacterial activity against Escherichia coli CSH-2 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID278534Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium animalis ATCC 27536 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1241206Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID703485Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID278561Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium breve ATCC 15700 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID428870Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID278545Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium animalis ATCC 27536 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID752510Antibacterial activity against Streptococcus pyogenes JRS75 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID579902Cytotoxicity against mouse J774A1 cells by MTT assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents.
AID1570827Selectivity ratio of IC50 for anti-ribosomal activity against human-bacterial hybrid ribosome containing human mitochondrial ribosome A site harboring wild type 12s rRNA to IC50 for anti-ribosomal activity against bacterial 70S hybrid ribosomes2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID351936Suppression of PCDH15 R245X nonsense mutant cDNA translation in TNT rabbit reticulocyte lysate transcription translation system at 25 to 100 uM at 30 degC after 90 mins by luciferase reporter gene assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID539120Antibacterial activity against Staphylococcus aureus ATCC 137092010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria.
AID278560Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium bifidum BB12 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1881658Inhibition of human mitochondrial ribosome Mit 13 A1555G mutant hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID514826Binding affinity to Escherichia coli 23S rRNA assessed as increase in classical-state occupancy by tRNA at 20 uM by smFRET2010Nature chemical biology, Jan, Volume: 6, Issue:1
Aminoglycoside activity observed on single pre-translocation ribosome complexes.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID65059Concentration required for half maximum rate of enhanced [3H]DHS uptake in Escherichia coli K121987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID523405Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID278803Antimicrobial activity against recombinant Escherichia coli DHalpha expressing pBAD [aph(3')-2]2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID752521Antibacterial activity against Staphylococcus aureus NCTC 6571 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID278565Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium longum R0175 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278542Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium longum P/N 601377 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID539119Antibacterial activity against Escherichia coli ATCC 259222010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria.
AID428869Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID288089Affinity to hairpin A-site 16S rRNA by Electrospray ionization mass spectrometry2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching.
AID351923Toxicity against HEK293 cells2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID278527Antimicrobial activity against Bifidobacterium longum ATCC 157072007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1575870Inhibition of Mycobacterium smegmatis wild type ribosomes assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID1468973Antileishmanial activity against Leishmania major MPRO/SA/85/JISH118 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID1241214Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of 15-mer DNA2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID278540Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium longum ATCC 15707 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1881660Selectivity ratio of IC50 for inhibition of human mitochondrial ribosome Mit 13 hybridized with Mycobacterium smegmatis ribosome to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID278546Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium bifidum R0071 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278538Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium breve R0070 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID307262Ratio of Kcat/Km of bacterial APH(3')-3a kinase-mediated low affinity phosphorylation2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
6-hydroxy to 6'''-amino tethered ring-to-ring macrocyclic aminoglycosides as probes for APH(3')-IIIa kinase.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1468961Antileishmanial activity against Leishmania donovani MHOM/SD/62/ISCL2D amastigotes expressing Luc gene infected in mouse J774A.1 cells after 3 to 5 days by luciferase reporter gene assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID278804Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD [aph(3')-2] in the presence of arabinose2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID199517Compound was tested for the inhibition of Rev-RBE RNA complex formation1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.
AID703476Therapeutic index, ratio of IC50 for mouse Peritoneal macrophages to IC50 for SSG-resistant Leishmania donovani 39 amastigote infected in mouse peritoneal macrophages2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID540931Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP1 harboring rpsL A262G and C271T mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1069849Antibacterial activity against kanamycin-resistant Escherichia coli K-12 JW 5503-1 harboring tolc732 deletion mutant assessed as growth inhibition after 18 hrs by geometric microdilution method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Rigid spiroethers targeting the decoding center of the bacterial ribosome.
AID540934Binding affinity to Streptomyces coelicolor KO-178 30S ribosomal protein S12 K88E mutant assessed as inhibition of protein synthesis at 0.2 ug/ml by fluorescence assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID278562Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium breve R0070 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID307260Activity of bacterial APH(3')-3a kinase assessed low affinity phosphorylation2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
6-hydroxy to 6'''-amino tethered ring-to-ring macrocyclic aminoglycosides as probes for APH(3')-IIIa kinase.
AID664699Antimicrobial activity against Staphylococcus aureus harboring APH(2'''') and AAC(6') enzymes2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID278555Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium longum P/N 601377 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID260536Reduction of oocyst in stools of Cryptosporidium parvum infected gerbils treated with 100 mg/kg at day 82006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID278893Inhibition of Escherichia coli XL1-Blue IF3 antiassociation activity at 0.1 uM in the presence of 8.2 mM Mg2+2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
AID212744Inhibition of telomerase before assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID278553Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium longum ATCC 15708 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID523398Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 5 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID1631084Inhibition of TDP1 (unknown origin) using 14-mer duplex oligonucleotide [32P]-D14Y as substrate incubated for 20 mins by PAGE analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
AID1575865Selectivity ratio of IC50 for inhibition of human mitochondrial ribosome Mit 13 A1555G mutant hybridized with Mycobacterium smegmatis ribosomes to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID752513Antibacterial activity against Streptococcus pyogenes serotype M3 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID754988Antileishmanial activity against amastigote stage of Leishmania donovani infected in mouse J774A.1 cells assessed as parasite growth inhibition after 72 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.
AID1241215Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of 15-mer DNA to Kd for 5'-FAM-pre-miR-372 (unknown origin)2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID752511Antibacterial activity against Streptococcus pyogenes serotype M24 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID1570824Antibacterial activity against Escherichia coli AG001 incubated for overnight by broth microdilution assay2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID752519Antibacterial activity against biofilm-negative Staphylococcus epidermidis ATCC 12228 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID278550Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium breve R0070 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID351924Toxicity against african green monkey COS7 cells2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID1468965Antileishmanial activity against Leishmania donovani isolate GR265 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID278566Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium longum P/N 601377 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278559Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium bifidum R0071 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID126451Dissociation constant for binding to mitochondrial 12S rRNA construct M4 was determined2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Decoding region bubble size and aminoglycoside antibiotic binding.
AID754985Antileishmanial activity against amastigote stage of Leishmania donovani infected in golden hamster assessed as inhibition of parasite multiplication at 50 mg/kg, ip administered 5 days measured on day 7 by Giemsa staining assay relative to control2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.
AID1468966Antileishmanial activity against Leishmania infantum isolate LEM5695 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID533157Antileishmanial activity against intracellular Leishmania donovani LV82 amastigotes infected in CD-1 mouse peritoneal macrophage2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID703621Antimicrobial activity against wild-type Leishmania donovani AG83 promastigote assessed as inhibition of parasite growth after 72 hrs by MTS assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID166719Tested for binding affinity against RNA construct E2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID1881657Inhibition of human mitochondrial ribosome Mit 13 hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID703487Antimicrobial activity against pentamidine-resistant Leishmania donovani AG83PentR50 promastigote assessed as inhibition of parasite growth after 72 hrs by MTS assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID752512Antibacterial activity against Streptococcus pyogenes serotype M5 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID278895Association of ribosome subunits into 70S ribosome of Escherichia coli MRE600 in presence of 4 mM Mg2+2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
AID703483Therapeutic index, ratio of IC50 for mouse PEM cells to IC50 for wild-type Leishmania donovani AG83 promastigote2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID271282Binding affinity to bacterial ribosomal A site RNA oligonucleotide2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies.
AID1069852Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition after 18 hrs by geometric microdilution method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Rigid spiroethers targeting the decoding center of the bacterial ribosome.
AID278531Antimicrobial activity against Bifidobacterium pseudolongum ATCC 255622007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID572373Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in trophozoites in ileum at 100 mg/kg/day, po for 6 days by hematoxylin and eosin staining2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1241208Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID696372Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in golden hamster assessed as inhibition of parasite growth at 50 mg/kg, ip for 5 days post infection measured on day 7 by Giemsa staining2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Chemotherapy of leishmaniasis. Part XI: synthesis and bioevaluation of novel isoxazole containing heteroretinoid and its amide derivatives.
AID572372Antimicrobial activity against Cryptosporidium parvum GCH1 infected in MDBK cells after 48 hrs by ELISA2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID513832Binding affinity to Escherichia coli 16S rRNA helix 44 assessed as classical-state occupancy by tRNA (Rvb= 62.4+/-1.1%)2010Nature chemical biology, Jan, Volume: 6, Issue:1
Aminoglycoside activity observed on single pre-translocation ribosome complexes.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1241211Binding affinity to 5'-FAM-pre-miR-373 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID278549Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium breve ATCC 15700 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID752514Antibacterial activity against Streptococcus pyogenes serotype M2 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID278802Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD in the presence of arabinose2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID523397Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID533154Antileishmanial activity against intracellular Leishmania donovani LV82 amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID351919Suppression of CFTR W1282X nonsense mutant cDNA translation in TNT rabbit reticulocyte lysate transcription translation system at 25 to 100 uM at 30 degC after 90 mins by luciferase reporter gene assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID228764Minimum inhibitory concentration required against bacterial transcription/translation2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
2-piperidin-4-yl-benzimidazoles with broad spectrum antibacterial activities.
AID278551Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium infantis ATCC 15697 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID703484Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID579901Antileishmanial activity against amastigotes of Leishmania donovani2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents.
AID212743Inhibition of telomerase after assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID126452Dissociation constant for binding to mitochondrial 12S rRNA construct M5 was determined2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Decoding region bubble size and aminoglycoside antibiotic binding.
AID207327Antibacterial activity determined against Staphylococcus aureus2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
2-piperidin-4-yl-benzimidazoles with broad spectrum antibacterial activities.
AID278526Antimicrobial activity against Bifidobacterium infantis ATCC 156972007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID579900Antileishmanial activity against promastigotes of Leishmania donovani at 10 ug/ml2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents.
AID1881661Selectivity ratio of IC50 for inhibition of human mitochondrial ribosome Mit 13 A1555G mutant hybridized with Mycobacterium smegmatis ribosomes to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID278563Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium longum ATCC 15707 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID533153Antileishmanial activity against Leishmania donovani axenic amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID1241212Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of Escherichia coli tRNA2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1575869Inhibition of human mitochondrial ribosome Mit 13 hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID703620Antimicrobial activity against SSG-resistant Leishmania donovani 39 promastigote assessed as inhibition of parasite growth after 72 hrs by MTS assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID1069847Antibacterial activity against kanamycin-resistant Escherichia coli K-12 JW 0451-2 harboring acrB747 deletion mutant assessed as growth inhibition after 18 hrs by geometric microdilution method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Rigid spiroethers targeting the decoding center of the bacterial ribosome.
AID238131Binding dissociation constant towards 3'-Fl-AM1A-Rhd in Bacillus subtilis tyrS2005Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8
Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA.
AID540932Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP2 harboring rpsL K88E mutant gene and inserted glycine at position 92 of the gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1241203Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID278537Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium breve ATCC 15700 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1241213Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of Escherichia coli tRNA to Kd for 5'-FAM-pre-miR-372 (unknown origin)2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1595002Antileishmanial activity against promastigote stage of Leishmania donovani assessed as parasite growth inhibition after 72 hrs by resazurin dye based assay2019European journal of medicinal chemistry, May-15, Volume: 170Evaluation of synthetic substituted 1,2-dioxanes as novel agents against human leishmaniasis.
AID1069848Antibacterial activity against kanamycin-resistant Escherichia coli K-12 JW 3596-1 harboring rfaC733 deletion mutant assessed as growth inhibition after 18 hrs by geometric microdilution method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Rigid spiroethers targeting the decoding center of the bacterial ribosome.
AID65062Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1468959Antileishmanial activity against Leishmania donovani MHOM/ET/67/HU3 amastigotes expressing Luc gene infected in mouse J774A.1 cells after 3 to 5 days by luciferase reporter gene assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID278897Association of ribosome subunits into 70S ribosome of Escherichia coli MRE600 in presence of 6 mM Mg2+2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
AID1468963Antileishmanial activity against sodium stibogluconate resistant Leishmania donovani isolate BHU1 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID752520Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID703481Therapeutic index, ratio of IC50 for mouse Peritoneal macrophages to IC50 for SSG-resistant Leishmania donovani 39 promastigote2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID351921Suppression of IDUA Q70X nonsense mutant cDNA translation in TNT rabbit reticulocyte lysate transcription translation system at 25 to 100 uM at 30 degC after 90 mins by luciferase reporter gene assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID1881659Inhibition of human cytoplasmic ribosome Cyt 14 hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID1570828Selectivity ratio of Kd for 5'-fluorescein-tagged human mitochondrial ribosomal A site wt-duplex RNA to Kd for 5'-fluorescein-tagged Escherichia coli ribosomal A site wt-bac duplex RNA2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID278564Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium longum ATCC 15708 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278539Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium infantis ATCC 15697 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1468970Antileishmanial activity against Leishmania infantum isolate LEM3323 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID1881662Selectivity ratio of IC50 for inhibition of human cytoplasmic ribosome Cyt 14 hybridized with Mycobacterium smegmatis ribosomes to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID533155Antileishmanial activity against intracellular Leishmania amazonensis amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID1069851Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition after 18 hrs by geometric microdilution method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Rigid spiroethers targeting the decoding center of the bacterial ribosome.
AID1575866Selectivity ratio of IC50 for inhibition of human mitochondrial ribosome Mit 13 hybridized with Mycobacterium smegmatis ribosome to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID1575868Inhibition of human cytoplasmic ribosome Cyt 14 hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID540935Binding affinity to Streptomyces coelicolor KO-347 30S ribosomal ptotein S12 GI92 mutant assessed as inhibition of protein synthesis at 0.2 ug/ml by fluorescence assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID286989Antimicrobial activity against Staphylococcus aureus ATCC 13709 after 20 to 24 hrs2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Structure-based design, synthesis, and A-site rRNA cocrystal complexes of functionally novel aminoglycoside antibiotics: C2" ether analogues of paromomycin.
AID428873Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID260532Deparasitization of Cryptosporidium parvum infected gerbils treated with 100 mg/kg at day 82006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo.
AID649981Antiparasitic activity against Cryptosporidium parvum infection model2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH.
AID126449Dissociation constant for binding to mitochondrial 12S rRNA construct M2 was determined2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Decoding region bubble size and aminoglycoside antibiotic binding.
AID278898Association of ribosome subunits into 70S ribosome of Escherichia coli MRE600 assessed upto 20 uM in the presence of 1 mM Mg2+2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
AID1570821Binding affinity to 5'-fluorescein-tagged human mitochondrial ribosomal A site wt-duplex RNA incubated for 2 mins by fluorescence spectrophotometric analysis2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID166717Tested for binding affinity against RNA construct D2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID351917Binding affinity to human cytoplasmic ribosomal RNA A-site2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID752518Antibacterial activity against biofilm-positive Staphylococcus epidermidis RP62A ATCC 35984 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID375076Binding affinity to A-site RNA2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID1468960Antileishmanial activity against Leishmania infantum MHOM/MA/67/ITMAP263 amastigotes infected in mouse primary peritoneal macrophages after 5 days by Giemsa staining based microscopic method2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID540929Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor KO-347 harboring rpsl P91S mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID351926Acute toxicity in iv dosed BALB/c mouse assessed as mortality administered as single dose after 4 days2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID752509Antibacterial activity against glossy colony producing Streptococcus pyogenes assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID1241209Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID664697Antimicrobial activity against Staphylococcus aureus harboring APH(3'/5'''')-3 enzyme2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID1468971Antileishmanial activity against Leishmania aethiopica MHOM/ET/84/KH after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID1881663Antibacterial activity against methicillin-resistant Staphylococcus aureus AG0382021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID1881666Antibacterial activity against Klebsiella pneumoniae AG2152021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID1468967Antileishmanial activity against Leishmania infantum isolate MCAN/BR/2002/BH400 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID1570822Binding affinity to 5'-fluorescein-tagged human mitochondrial ribosome A site mutant duplex RNA incubated for 2 mins by fluorescence spectrophotometry analysis2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID1570830Selectivity ratio of Kd for 5'-fluorescein-tagged human mitochondrial ribosome A site mutant duplex RNA to Kd for 5'-fluorescein-tagged Escherichia coli ribosomal A site wt-bac duplex RNA2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID278544Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium thermophilum ATCC 25866 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278532Antimicrobial activity against Bifidobacterium thermophilum ATCC 258662007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID513836Binding affinity to Escherichia coli 16S rRNA helix 44 assessed as tRNA translocation rate (Rvb= 1.57+/-0.05 /sec)2010Nature chemical biology, Jan, Volume: 6, Issue:1
Aminoglycoside activity observed on single pre-translocation ribosome complexes.
AID351927Antibacterial activity against Escherichia coli R477-100 by double-microdilution method2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID1570820Binding affinity to 5'-fluorescein-tagged Escherichia coli ribosomal A site wt-bac duplex RNA incubated for 2 mins by fluorescence spectrophotometric analysis2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID1881667Antibacterial activity against Enterobacter cloacae AG2902021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID278543Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium pseudolongum ATCC 25562 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID540928Antimicrobial activity against streptomycin-resistant Streptomyces coelicolor KO-178 harboring rpsL K88E mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID278525Antimicrobial activity against Bifidobacterium breve ATCC 157002007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID572165Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID278896Association of ribosome subunits into 70S ribosome of Escherichia coli MRE600 at 0.1 mM in presence of 4 mM Mg2+2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
AID351922Suppression of PCDH15 R3X nonsense mutant cDNA translation in TNT rabbit reticulocyte lysate transcription translation system at 25 to 100 uM at 30 degC after 90 mins by luciferase reporter gene assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID754987Cytotoxicity against african green monkey vero cells assessed as cell viability after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.
AID1881668Antibacterial activity against Pseudomonas aeruginosa AG0312021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID278554Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium longum R0175 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID572376Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in number of trophozoites at 100 mg/kg/day, po for 6 days2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID1468964Antileishmanial activity against Leishmania donovani isolate SUKA001 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID278547Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium bifidum ATCC 15696 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID82136Binding to 176-mer RNA from the packaging region of HIV-1 (LAI) and value of binding constant K is determined2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Absorption studies on aminoglycoside binding to the packaging region of human immunodeficiency virus type-1.
AID286988Antimicrobial activity against Escherichia coli ATCC 25922 after 20 to 24 hrs2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Structure-based design, synthesis, and A-site rRNA cocrystal complexes of functionally novel aminoglycoside antibiotics: C2" ether analogues of paromomycin.
AID514831Binding affinity to Escherichia coli 23S rRNA G2553C mutant assessed as increase in classical-state occupancy by tRNA at 20 uM by smFRET2010Nature chemical biology, Jan, Volume: 6, Issue:1
Aminoglycoside activity observed on single pre-translocation ribosome complexes.
AID166713Tested for binding affinity against RNA construct B2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID278552Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium longum ATCC 15707 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1575867Inhibition of human mitochondrial ribosome Mit 13 A1555G mutant hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID572370Antimicrobial activity against Cryptosporidium parvum infected in neonatal ICR swiss mouse assessed as reduction in oocyst shedding at 50 mg/kg/day, po measured on day 62008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID752516Antibacterial activity against Streptococcus pyogenes MGAS9429 assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-15, Volume: 21, Issue:12
Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
AID1570826Anti-ribosomal activity against human-bacterial hybrid ribosome containing human mitochondrial ribosome A site harboring wild type 12s rRNA assessed as inhibition of cell-free translation by dual luciferase reporter assay2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID207516Minimal inhibitory concentration against Staphylococcus aureus (Range is 1-3 uM)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents.
AID278805Antimicrobial activity against Stenotrophomonas maltophilia K279a mutant2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID278523Antimicrobial activity against Bifidobacterium bifidum ATCC 156962007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1241205Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID65067Percent killing of the total Escherichia coli K12 (ATCC 25868)cells at the C50 concentration was determined.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1570825Anti-ribosomal activity against human-bacterial hybrid ribosome containing human mitochondrial ribosome A site harboring A1555G mutant 12s rRNA assessed as inhibition of cell-free translation by dual luciferase reporter assay2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID278548Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium bifidum BB12 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278899Association of ribosome subunits into 70S ribosome of Escherichia coli MRE600 assessed above 20 uM in the presence of 1 mM Mg2+2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID754989Antileishmanial activity against promastigote stage of Leishmania donovani assessed as parasite growth inhibition at 25 uM after 72 hrs by luciferase reporter gene assay relative to untreated control2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.
AID1468976Antileishmanial activity against Leishmania tropica isolate Anwari after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351937Suppression of IDUA W402X nonsense mutant cDNA translation in TNT rabbit reticulocyte lysate transcription translation system at 25 to 100 uM at 30 degC after 90 mins by luciferase reporter gene assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID1241210Binding affinity to 5'-FAM-pre-miR-17 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID236835Maximum Frel value for binding to 3'-Fl-AM1A-Rhd in Bacillus subtilis tyr2005Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8
Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA.
AID212902Inhibition of human telomerase after assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1241204Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID351939Suppression of PCDH15 R3X nonsense mutant cDNA translation in african green monkey COS7 cells at 0.5 mg/mL2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID278557Antimicrobial activity against 90 mins oxgall-stressed Bifidobacterium thermophilum ATCC 25866 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID351925Toxicity against MDCK cells2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540927Antimicrobial activity against Streptomyces coelicolor 1147 after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID572371Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells assessed as growth inhibition after 48 hrs by ELISA2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID572359Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in oocyst shedding at 100 mg/kg/day, po for 4 days treated 3 days postinfection2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID238114Dissociation constant of the compound2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Validation of automated docking programs for docking and database screening against RNA drug targets.
AID1699378Antileishmanial activity against Leishmania donovani MHOM/MA(BE)/67/ITMAP263 promastigotes infected in primary mouse peritoneal macrophage assessed as reduction in parasite viability measured after 4 days by Giemsa staining-based assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.
AID1575864Selectivity ratio of IC50 for inhibition of human cytoplasmic ribosome Cyt 14 hybridized with Mycobacterium smegmatis ribosomes to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID278806Antimicrobial activity against Stenotrophomonas maltophilia K279a (aph FS) mutant2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1241225Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) assessed as change in total free energy by thermodynamic assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID278530Antimicrobial activity against Bifidobacterium longum P/N 6013772007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1662707Ototoxicity against C57BL/6 mouse cochlea hair cells assessed as reduction in cell viability at 0.1 mM incubated for 23 hrs by FITC-phalloidin staining-based assay2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
The relationship between the structure and toxicity of aminoglycoside antibiotics.
AID703482Therapeutic index, ratio of IC50 for mouse Peritoneal macrophages to IC50 for pentamidine-resistant Leishmania donovani AG83PentR50 promastigote2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID586923Resistant index, ratio of EC50 for tafenoquine-resistant promastigotes of Leishmania major R4 to EC50 for promastigotes of Leishmania major MHOM/JL/80/Friedlin2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID1069850Antibacterial activity against Escherichia coli ATCC 25922 assessed as growth inhibition after 18 hrs by geometric microdilution method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Rigid spiroethers targeting the decoding center of the bacterial ribosome.
AID278522Antimicrobial activity against Bifidobacterium bifidum R00712007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID69039Minimal inhibitory concentration against Escherichia coli (Range is 3-6 uM)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID278533Antimicrobial activity against Bifidobacterium breve R00702007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1241201Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID734605Selectivity ratio of Kd for Escherichia coli H69-UUU RNA to Kd for wild type Escherichia coli H69 RNA2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Selection of heptapeptides that bind helix 69 of bacterial 23S ribosomal RNA.
AID278801Antimicrobial activity against recombinant Escherichia coli DH5alpha expressing pBAD2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID1881665Antibacterial activity against Acinetobacter baumannii AG2252021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID65071Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868)1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1468975Antileishmanial activity against Leishmania panamensis MHOM/PA/67/Boyton after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID278528Antimicrobial activity against Bifidobacterium longum ATCC 157082007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278521Antimicrobial activity against Bifidobacterium animalis ATCC 275362007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID428872Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID351918Suppression of CFTR G542X nonsense mutant cDNA translation in TNT rabbit reticulocyte lysate transcription translation system at 25 to 100 uM at 30 degC after 90 mins by luciferase reporter gene assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID533156Antileishmanial activity against intracellular Leishmania major amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID1241202Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID166711Tested for binding affinity against RNA construct A2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID754986Selectivity index, ratio of CC50 for african green monkey vero cells to IC50 for amastigote stage of Leishmania donovani infected in mouse J774A.1 cells2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.
AID1881656Inhibition of Mycobacterium smegmatis wild type ribosomes assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID288090Affinity to 2-aminopurine labeled hairpin A-site 16S rRNA by Electrospray ionization mass spectrometry2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching.
AID572362Antimicrobial activity against Cryptosporidium parvum infected in neonatal BALB/C mouse assessed as reduction in oocyst shedding at 100 mg/kg/day, po for 6 days treated 3 days postinfection2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
AID278558Antimicrobial activity against 90 mins hydrogen peroxide-stressed Bifidobacterium animalis ATCC 27536 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID2940Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Which aminoglycoside ring is most important for binding? A hydropathic analysis of gentamicin, paromomycin, and analogues.
AID523396Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID1881664Antibacterial activity against Escherichia coli AG0012021RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9
Influence of ring size in conformationally restricted ring I analogs of paromomycin on antiribosomal and antibacterial activity.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID278894Inhibition of Escherichia coli XL1-Blue IF3 binding to 30S subunit at 100 uM in presence of 8.2 mm Mg2+2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibition of antiassociation activity of translation initiation factor 3 by paromomycin.
AID664698Antimicrobial activity against Staphylococcus aureus harboring ANT(4')-1 enzyme2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID1570829Selectivity ratio of IC50 for anti-ribosomal activity against human-bacterial hybrid ribosome containing human mitochondrial ribosome A site harboring A1555G mutant 12s rRNA to IC50 for anti-ribosomal activity against bacterial 70S hybrid ribosomes2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID1570823Anti-ribosomal activity against bacterial 70S hybrid ribosomes assessed as inhibition of cell-free translation incubated for 35 mins by dual luciferase reporter assay2019Bioorganic & medicinal chemistry, 11-15, Volume: 27, Issue:22
Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.
AID278529Antimicrobial activity against Bifidobacterium longum R01752007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID278541Antimicrobial activity against 60 min 1 M HCl-stressed Bifidobacterium longum R0175 after 18 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.
AID1468972Antileishmanial activity against Leishmania amazonensis MPRO/BR/72/M1841 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID1468969Antileishmanial activity against miltefosine resistant Leishmania infantum isolate LEM5159 after 3 to 5 days2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
AID351934Inhibition of protein translation in Escherichia coli by coupled transcription/translation assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
AID540930Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor 92G harboring rpsL gene with inserted glycine at position 92 after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID703486Antimicrobial activity against SSG-resistant Leishmania donovani 39 amastigote infected in mouse peritoneal macrophages assessed as inhibition of parasite growth after 72 hrs by Giemsa staining method2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Flavonoid dimers as novel, potent antileishmanial agents.
AID579903Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for amastigotes of Leishmania donovani2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,315)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990523 (39.77)18.7374
1990's199 (15.13)18.2507
2000's271 (20.61)29.6817
2010's267 (20.30)24.3611
2020's55 (4.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.21 (24.57)
Research Supply Index7.32 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index108.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials90 (6.33%)5.53%
Reviews95 (6.68%)6.00%
Case Studies115 (8.09%)4.05%
Observational1 (0.07%)0.25%
Other1,121 (78.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh [NCT01328457]120 participants (Actual)Interventional2011-01-31Completed
A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh [NCT01122771]Phase 3602 participants (Actual)Interventional2010-05-31Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Mechanical Bowel Preparation and Oral Antibiotic Prophylaxis vs. Mechanical Bowel Preparation in Colorectal Surgery With i.v. Antibiotic Prophylaxis [NCT03759886]100 participants (Anticipated)Observational [Patient Registry]2018-12-17Recruiting
A Randomized, Open-label, Phase II, Single-centre Study to Evaluate the Efficacy, Safety and Pharmacokinetics of LXE408 in Patients With Primary Visceral Leishmaniasis in Ethiopia [NCT05957978]Phase 252 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Multicentre Observational Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis [NCT04342715]280 participants (Anticipated)Observational2022-05-22Recruiting
An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa [NCT03129646]Phase 3439 participants (Actual)Interventional2018-01-24Completed
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: a Phase 2 Study in the Old World [NCT00703924]Phase 292 participants (Actual)Interventional2003-03-31Completed
Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Peru [NCT01032382]Phase 230 participants (Actual)Interventional2010-01-31Completed
Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (t [NCT00696969]Phase 3634 participants (Actual)Interventional2008-06-30Completed
A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis [NCT00604955]Phase 42,000 participants (Actual)Interventional2007-10-31Completed
Pilot Study of Efficacy of Topical Nano-liposomal Meglumine Antimoniate (Glucantime) or Paromomycin in Combination With Systemic Glucantime for the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Caused by Leishmania Tropica [NCT01050777]Early Phase 130 participants (Anticipated)Interventional2011-03-31Completed
An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) [NCT00629031]Phase 3329 participants (Actual)Interventional2008-02-29Completed
A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) [NCT00606580]Phase 3375 participants (Actual)Interventional2008-01-31Completed
Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama [NCT01083576]Phase 230 participants (Actual)Interventional2010-03-31Completed
A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) [NCT00523965]Phase 3624 participants (Anticipated)Interventional2007-09-30Completed
Open-label Treatment of Non-complicated, Non-severe, Cutaneous Leishmaniasis in Tunisia With WR 279,396 (Paromomycin + Gentamicin Topical Cream) ) [NCT01494350]Phase 250 participants (Actual)Interventional2011-12-31Terminated(stopped due to This study was closed prematurely due study team travel restrictions.)
A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS [NCT00001128]16 participants InterventionalTerminated
A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis [NCT00216346]Phase 3667 participants Interventional2003-06-30Completed
Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 [NCT00657917]Phase 21 participants (Actual)Interventional2006-12-20Terminated(stopped due to No subjects were enrolled since the first subject completed the study 08Jun2007)
An Open-Label Clinical Study to Examine the Safety, Efficacy, and Pharmacokinetics of WR 279,396 (Paromomycin + Gentamicin Topical Cream) for the Treatment of Cutaneous Leishmaniasis at Walter Reed National Military Medical Center (WRNMMC) [NCT01140191]Phase 21 participants (Actual)Interventional2013-09-30Terminated(stopped due to This study was closed due to lack of enrollment (only one subject enrolled))
A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan [NCT00255567]Phase 31,142 participants (Actual)Interventional2004-11-30Completed
Paromomycin Topical Cream Treatment Protocol for Individuals With Uncomplicated Cutaneous Leishmaniasis [NCT01641796]0 participants Expanded AccessNo longer available
The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit. Evaluatie Van de Gastrointestinale Transit Aan de Hand Van de Niet-absorbeerbare Merker Paromomycine Sulfaat (Dutch Translation) [NCT01780909]10 participants (Anticipated)Interventional2013-02-28Recruiting
A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 [NCT00000771]Phase 268 participants InterventionalCompleted
[NCT00004444]24 participants Interventional1994-11-30Completed
A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama [NCT01790659]Phase 3399 participants (Actual)Interventional2013-05-31Completed
Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study [NCT03096457]Phase 2/Phase 380 participants (Actual)Interventional2017-04-15Completed
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis [NCT03829917]Phase 2/Phase 3120 participants (Actual)Interventional2019-02-01Completed
An Open Label, Randomized, Parallel Arm Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in Sudan [NCT03399955]Phase 2110 participants (Anticipated)Interventional2018-05-09Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00606580 (12) [back to overview]Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 42
NCT00606580 (12) [back to overview]Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 49
NCT00606580 (12) [back to overview]Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 98
NCT00606580 (12) [back to overview]Estimated Percentage Subjects With Re-epithelialization of the Index Lesion Without Relapse
NCT00606580 (12) [back to overview]Final Clinical Cure Rate
NCT00606580 (12) [back to overview]Final Clinical Cure Rate (Per Protocol Dataset)
NCT00606580 (12) [back to overview]Number of All Ulcerated Lesions Achieving 100% Re-epithelialization by Day 42
NCT00606580 (12) [back to overview]Number of Subjects Achieving Initial Clinical Improvement of the Index Lesion
NCT00606580 (12) [back to overview]Number of Subjects Achieving Re-epithelialization of All Treated Ulcerated Lesions Without Subsequent Relapse
NCT00606580 (12) [back to overview]Number of Subjects Achieving Re-epithelialization of the Index Lesion Without Relapse
NCT00606580 (12) [back to overview]Number of Subjects With a Relapse on or After Day 42
NCT00606580 (12) [back to overview]Estimated Percentage of Subjects With Re-epithelialization of the Index Lesion Without Relapse at Various Times of Follow-up
NCT00657917 (3) [back to overview]Number of Relapses
NCT00657917 (3) [back to overview]Safety and Tolerability (SAE's and AE's)
NCT00657917 (3) [back to overview]The Appearance of Complete Epithelialization of Ulcerative Lesions Caused by Old World Cutaneous Leishmaniasis With no Relapse
NCT00703924 (3) [back to overview]Safety of WR 279,396 (AEs and SAEs)
NCT00703924 (3) [back to overview]Time to Complete Re-epithelialization of the Index Lesion Ulcer Without Relapse
NCT00703924 (3) [back to overview]Rate of Relapse
NCT01032382 (11) [back to overview]Final Clinical Cure for Index Lesions
NCT01032382 (11) [back to overview]Final Clinical Cure on All Lesions Independent of Subjects
NCT01032382 (11) [back to overview]Detectable Paromomycin Plasma Levels
NCT01032382 (11) [back to overview]Number of Index Lesions Meeting Criteria for Clinical Cure During the Study
NCT01032382 (11) [back to overview]Pharmacokinetic Parameter: Area Under the Curve (AUC)
NCT01032382 (11) [back to overview]Pharmacokinetic Parameter: AUC/D
NCT01032382 (11) [back to overview]Pharmacokinetic Parameter: Cmax
NCT01032382 (11) [back to overview]Pharmacokinetic Parameter: Cmax/D
NCT01032382 (11) [back to overview]Pharmacokinetic Parameter: t(1/2)
NCT01032382 (11) [back to overview]Pharmacokinetic Parameter: Tmax
NCT01032382 (11) [back to overview]Paromomycin Plasma Concentrations in Children
NCT01083576 (12) [back to overview]Paromomycin Plasma Concentrations in Adults
NCT01083576 (12) [back to overview]Paromomycin Plasma Concentrations in Children
NCT01083576 (12) [back to overview]Pharmacokinetic Parameter: Area Under the Curve (AUC)
NCT01083576 (12) [back to overview]Pharmacokinetic Parameter: AUC/D
NCT01083576 (12) [back to overview]Pharmacokinetic Parameter: Cmax
NCT01083576 (12) [back to overview]Pharmacokinetic Parameter: Cmax/D
NCT01083576 (12) [back to overview]Pharmacokinetic Parameter: t(1/2)
NCT01083576 (12) [back to overview]Pharmacokinetic Parameter: Tmax
NCT01083576 (12) [back to overview]Serum Creatinine Levels
NCT01083576 (12) [back to overview]Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions
NCT01083576 (12) [back to overview]Number of Participants Who Obtained Final Clinical Cure of Index Lesion
NCT01083576 (12) [back to overview]Detectable Paromomycin or Gentamicin Plasma Levels
NCT01140191 (6) [back to overview]100% Re-epithelialization of Index Lesion by Nominal Day 60
NCT01140191 (6) [back to overview]Complete Cure of Index Lesion by Day 100
NCT01140191 (6) [back to overview]Cures of All Other Lesions
NCT01140191 (6) [back to overview]Number of Adverse Events
NCT01140191 (6) [back to overview]Number of Participants Demonstrating Initial Clinical Improvements
NCT01140191 (6) [back to overview]Number of Participants With No Relapse of Index Lesion Between Nominal Day 60 and 100
NCT01494350 (5) [back to overview]Area of Index Lesions Throughout the Study
NCT01494350 (5) [back to overview]Number of Index Lesions With Reepithelialization Throughout the Study
NCT01494350 (5) [back to overview]Final Clinical Cure Rate for the Index Lesion
NCT01494350 (5) [back to overview]Number of All Ulcerated Lesions With Reepithelialization on Day 28
NCT01494350 (5) [back to overview]Area of All Ulcerated Lesions Throughout the Study
NCT01790659 (6) [back to overview]Median Time to Initial Clinical Cure for Index Lesions
NCT01790659 (6) [back to overview]Percent of Participants With Final Clinical Cure
NCT01790659 (6) [back to overview]Percentage of All Lesions Cured at Day 168 (Ignores Per Subject Cure Rate)
NCT01790659 (6) [back to overview]Percentage of Subjects With All Lesions Cured
NCT01790659 (6) [back to overview]Area of Ulceration (mm^2) All Treated Lesions at Each Measurement Time Point
NCT01790659 (6) [back to overview]Area of Ulceration (mm^2) of the Index Lesion at Each Measurement Time Point

Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 42

(NCT00606580)
Timeframe: Days 42

InterventionPercentage of lesions (Number)
WR 279,396 Topical Treament51.7
Paromomycin Alone Topical Treatment81.6
Vehicle Placebo Cream58.1

[back to top]

Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 49

(NCT00606580)
Timeframe: Days 49

Interventionpercentage of lesions (Number)
WR 279,396 Topical Treament81.4
Paromomycin Alone Topical Treatment90.4
Vehicle Placebo Cream64.9

[back to top]

Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 98

(NCT00606580)
Timeframe: Days 98

Interventionpercentage of lesions (Number)
WR 279,396 Topical Treament91.5
Paromomycin Alone Topical Treatment98.9
Vehicle Placebo Cream92.2

[back to top]

Estimated Percentage Subjects With Re-epithelialization of the Index Lesion Without Relapse

For the first of the above analyses, subjects were considered to have endpoint events at the first assessment on or before Day 42 where complete re-epithelialization occurred at the index lesion that was not followed by a later assessment where ulceration was present. Subjects who did not have complete re-epithelialization by Day 42 or who relapsed after Day 42 were censored in the analysis at the Day 42 assessment. This analysis was only to be conducted through Day 42. (NCT00606580)
Timeframe: Day 42

Interventionpercentage of participants (Number)
WR 279,396 Topical Treament67.2
Paromomycin Alone Topical Treatment68.8
Vehicle Placebo Cream48.8

[back to top]

Final Clinical Cure Rate

"Final clinical cure was defined as an index lesion that met the criteria for initial clinical cure without relapse. Definitions for index lesion outcomes were as follows:~Initial Clinical Improvement: At least 50% to 99% reduction in the size of the measured lesion from the baseline measurement by the Day 42 evaluation.~Initial Clinical Cure: 100% re-epithelialization (ie, a 0 x 0 length x width measurement) of the lesion at the nominal Day 42 evaluation, or initial clinical improvement followed by 100% re-epithelialization by Day 98.~Relapse: Initial clinical cure followed by re-ulceration by Day 168, or initial clinical improvement followed by lesion enlargement by Day 168.~Final Clinical Cure: Initial clinical cure without relapse through study Day 168.Clinical Failure: Lack of at least initial clinical improvement by Day 42, or relapse." (NCT00606580)
Timeframe: Day 42, 98, and 168

Interventionparticipants (Number)
WR 279,396 Topical Treament101
Paromomycin Alone Topical Treatment102
Vehicle Placebo Cream73

[back to top]

Final Clinical Cure Rate (Per Protocol Dataset)

Final clinical cure was defined as an index lesion that met the criteria for initial clinical cure without relapse. Definitions for index lesion outcomes as described in the primary outcome measure. (NCT00606580)
Timeframe: Day 42, 98, and 168

Interventionparticipants (Number)
WR 279,396 Topical Treament101
Paromomycin Alone Topical Treatment102
Vehicle Placebo Cream73

[back to top]

Number of All Ulcerated Lesions Achieving 100% Re-epithelialization by Day 42

(NCT00606580)
Timeframe: Day 42

InterventionUlcerated lesions (Number)
WR 279,396 Topical Treament190
Paromomycin Alone Topical Treatment218
Vehicle Placebo Cream160

[back to top]

Number of Subjects Achieving Initial Clinical Improvement of the Index Lesion

(NCT00606580)
Timeframe: Day 42

Interventionparticipants (Number)
WR 279,396 Topical Treament105
Paromomycin Alone Topical Treatment107
Vehicle Placebo Cream77

[back to top]

Number of Subjects Achieving Re-epithelialization of All Treated Ulcerated Lesions Without Subsequent Relapse

Number of Subjects Achieving Re-epithelialization of All Treated Ulcerated Lesions at Day 42 without Subsequent Relapse from Day 42 Onward, (NCT00606580)
Timeframe: Day 168

Interventionparticipants (Number)
WR 279,396 Topical Treament83
Paromomycin Alone Topical Treatment84
Vehicle Placebo Cream60

[back to top]

Number of Subjects Achieving Re-epithelialization of the Index Lesion Without Relapse

Number of Subjects Achieving Re-epithelialization of the Index Lesion by Day 42 without Relapse from Day 42 Onward, Imputing Relapse for any Subject with a Missing Visit after Day 42 (NCT00606580)
Timeframe: Day 168

Interventionparticipants (Number)
WR 279,396 Topical Treament84
Paromomycin Alone Topical Treatment84
Vehicle Placebo Cream62

[back to top]

Number of Subjects With a Relapse on or After Day 42

(NCT00606580)
Timeframe: Day 168

Interventionparticipants (Number)
WR 279,396 Topical Treament4
Paromomycin Alone Topical Treatment3
Vehicle Placebo Cream2

[back to top]

Estimated Percentage of Subjects With Re-epithelialization of the Index Lesion Without Relapse at Various Times of Follow-up

(NCT00606580)
Timeframe: Days 42, 49, and 98

,,
Interventionpercentage of participants (Number)
Day 42Day 49Day 98
Paromomycin Alone Topical Treatment68.581.599.2
Vehicle Placebo Cream49.457.190.9
WR 279,396 Topical Treament67.272.994.3

[back to top]

Number of Relapses

Evaluate the number of relapses occurring by day 180 (NCT00657917)
Timeframe: 180 days

InterventionNumber of relapses (Number)
Paromomycin +Gentamicin Topical Cream0

[back to top]

Safety and Tolerability (SAE's and AE's)

Evaluate safety and tolerability as measured by completion of a full prescribed treatment course, treatment interruptions, SAE's and AE's (NCT00657917)
Timeframe: 180 days

InterventionNumber of AE's (Number)
AEs Considered Related to Study DrugAE's Not Considered Related to Study Drug
Paromomycin +Gentamicin Topical Cream923

[back to top]

The Appearance of Complete Epithelialization of Ulcerative Lesions Caused by Old World Cutaneous Leishmaniasis With no Relapse

Appearance of complete (100%) epithelialization of a skin lesion at day 50+2 weeks, or the estimated 50%-99% re-epithelialization by day 50+2 weeks followed by complete eipithelialization by day 100+2 weeks, with both categories without relapse by day 180+30 days. Ulcer measured in millimeters. (NCT00657917)
Timeframe: 180 days

InterventionSurface area in millimeters squared (Number)
ScreeningDay 20+3Day 50+14Day 180+30 (photos only)
Paromomycin +Gentamicin Topical Cream2,1421,4881,4000

[back to top]

Safety of WR 279,396 (AEs and SAEs)

Safety was evaluated on each day during daily administration of the topical products. Subjects were observed and questioned for the occurrence of solicited local side effects (eg, pain, erythema, edema) and solicited systemic side effects (eg, vertigo, tinnitus, diminished hearing). Non-solicited AE evaluations included spontaneous reports from subjects and clinical observations. (NCT00703924)
Timeframe: 180 days

,
InterventionAdverse Events (Number)
Solicated AEs- MildSolicited AEs- ModerateSolicited AEs- SevereNon-Solicited AEs- MildNon-Solicited AEs- ModerateNon-Soliciated AEs- SevereSAEs
Placebo4052201000
WR 279,39649112131001

[back to top]

Time to Complete Re-epithelialization of the Index Lesion Ulcer Without Relapse

100% re-epithelialization of the index lesion without having had a relapse. The log-rank test was used to compare the time to complete re-epithelialization. (NCT00703924)
Timeframe: 180 days

,,,
InterventionParticipants (Count of Participants)
WR 279,396Placebo
Day 10049
Day 180 (+7 Days)11
Day 201020
Day 503410

[back to top]

Rate of Relapse

"Relapse is defined as enlargement of the index lesion compared to previous measurement at any time after day 50 (+ 7 days) or not demonstrating CCR by study day 180. CCR was compared using uncorrected Fisher's exact test.~Confidence intervals (95%) were constructed on the difference between the two group proportions. The log-rank test was used to compare the time to complete re-epithelialization of the index lesion without relapse. Cure of all subjects lesions was also compared using the Fisher's exact test. To adjust for baseline differences in the treatment groups, a linear model for the proportion of subjects achieving CCR was fit for each baseline variable of interest with covariates for treatment group and the baseline variable." (NCT00703924)
Timeframe: 180 days

InterventionParticipants (Count of Participants)
WR 279,3960
Placebo3

[back to top]

Final Clinical Cure for Index Lesions

"Final clinical cure was defined as follows:~Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,~Subject has initial clinical improvement (> 50% re-epithelialization of index lesion by nominal Day 63 followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,~Subject has no relapse of index lesion by Day 168. Relapse was defined as an index lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (> 0 x 0 mm measurement) by nominal day 168, or an index lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168." (NCT01032382)
Timeframe: Initial clinical cure by day 63 and no relapse by day 168

Interventionparticipants (Number)
Paromomycin Alone Treatment11
WR 279,3969

[back to top]

Final Clinical Cure on All Lesions Independent of Subjects

"Final clinical cure was defined as follows:~Subject has initial clinical cure (100% re-epithelialization of lesion by nominal Day 63); OR,~Subject has initial clinical improvement (> 50% re-epithelialization of lesion by nominal Day 63 followed by 100% re-epithelialization of the lesion on or before nominal Day 100; AND,~Subject has no relapse of lesion by Day 168. Relapse was defined as a lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (> 0 x 0 mm measurement) by nominal day 168, or a lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168." (NCT01032382)
Timeframe: Initial clinical cure by day 63 and no relapse by day 168

InterventionCured ulcerated lesions (Number)
Paromomycin Alone Treatment12
WR 279,39614

[back to top]

Detectable Paromomycin Plasma Levels

Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults (NCT01032382)
Timeframe: Day 4, 7, 12, 17, 20, 28

,
Interventionng/mL (Mean)
Day 4Day 7Day 12Day 17Day 20Day 28
Paromomycin Alone Treatment12.110.336.2210.087.30
WR 279,39637.317.978.9162.0128.00

[back to top]

Number of Index Lesions Meeting Criteria for Clinical Cure During the Study

Number of study participants who meet the criteria for clinical cure (100% re-epithelialization) at specified timepoints during the study. (NCT01032382)
Timeframe: Day 1, 4, 7, 12, 17, 20, 28, 35, 42, 49, 56, 63, 100, 168

,
InterventionLesions meeting clinical cure criteria (Number)
Day 1Day 4Day 7Day 12Day 17Day 20Day 28Day 35Day 42Day 49Day 56Day 63Day 100Day 168
Paromomycin Alone Treatment00000158101011111211
WR 279,39600000061111121010109

[back to top]

Pharmacokinetic Parameter: Area Under the Curve (AUC)

Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng*hr/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment315413331
WR 279,39612288955

[back to top]

Pharmacokinetic Parameter: AUC/D

Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: Days 1 and 20

,
Interventionhr/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment996.73335
WR 279,396340.53155

[back to top]

Pharmacokinetic Parameter: Cmax

Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment5111400
WR 279,396155.0882

[back to top]

Pharmacokinetic Parameter: Cmax/D

Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Intervention1/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment185368
WR 279,39645.9283

[back to top]

Pharmacokinetic Parameter: t(1/2)

t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment2.557.17
WR 279,3964.516.81

[back to top]

Pharmacokinetic Parameter: Tmax

Pharmacokinetic Parameter: Tmax (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment2.254.6
WR 279,39633

[back to top]

Paromomycin Plasma Concentrations in Children

Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children (NCT01032382)
Timeframe: 0 and 4 hours on days 1 and 20

,
Interventionng/mL (Mean)
Day 1 hour 0Day 1 hour 4Day 20 hour 0Day 20 hour 4
Paromomycin Alone Treatment6.271.293.8744.0
WR 279,39622.1322.089.21030.0

[back to top]

Paromomycin Plasma Concentrations in Adults

Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults (NCT01083576)
Timeframe: Day 4 to Day 28

,
Interventionng/mL (Mean)
Day 4Day 7Day 12Day 17Day 20Day 28
Paromomycin Alone Treatment013.16.644.054.60
WR 279,39617.817.626.426.331.40

[back to top]

Paromomycin Plasma Concentrations in Children

Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children (NCT01083576)
Timeframe: Days 1 and 20

,
Interventionng/mL (Mean)
Study Day 1Study Day 20
Paromomycin Alone Treatment116.3992.7
WR 279,39698.6634.2

[back to top]

Pharmacokinetic Parameter: Area Under the Curve (AUC)

Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng*hr/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment15715603
WR 279,396863.44740

[back to top]

Pharmacokinetic Parameter: AUC/D

Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: Days 1 and 20

,
Interventionhr/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment715.21725
WR 279,396345.91380

[back to top]

Pharmacokinetic Parameter: Cmax

Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment219.0751.0
WR 279,396121561.0

[back to top]

Pharmacokinetic Parameter: Cmax/D

Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Intervention1/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment104.0227
WR 279,39661.3179

[back to top]

Pharmacokinetic Parameter: t(1/2)

t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment7.035.3
WR 279,3964.07.0

[back to top]

Pharmacokinetic Parameter: Tmax

Tmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment2.72.2
WR 279,3962.82.2

[back to top]

Serum Creatinine Levels

Blood creatinine was measured to assess possible nephrotoxicity associated with aminoglycosides (NCT01083576)
Timeframe: Day 1 and Day 20

,
Interventionmg/dL (Mean)
Study Day 1Study Day 20
Paromomycin Alone Treatment0.830.77
WR 279,3960.790.76

[back to top]

Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions

Final cure as defined by the primary outcome measure AND and cure of all other lesions by Day 168. (100% re-epithelialization of all ulcerated lesions and resolution of all other type of lesions) (NCT01083576)
Timeframe: 168 days

InterventionParticipants (Number)
Paromomycin Alone Treatment8
WR 279,39613

[back to top]

Number of Participants Who Obtained Final Clinical Cure of Index Lesion

Number of participants who had initial clinical cure (100% re-epithelialization of index lesion by Day 63) OR initial clinical improvements (> 50% re-epithelialization of index lesion followed by Day 63 by 100% re-epithelialization of the index lesion on or before Day 100), AND no relapse of index lesion. (NCT01083576)
Timeframe: 168 days

InterventionParticipants (Number)
Paromomycin Alone Treatment9
WR 279,39613

[back to top]

Detectable Paromomycin or Gentamicin Plasma Levels

Proportion of subjects with any detectable Paromomycin or Gentamicin plasma levels on a study day when blood for PK was collected (NCT01083576)
Timeframe: 20 days

,
InterventionParticipants (Number)
Any detectable gentamicinAny detectable paromomycin
Paromomycin Alone Treatment08
WR 279,39618

[back to top]

100% Re-epithelialization of Index Lesion by Nominal Day 60

Number of participants with 100% re-epithelialization of index lesion by nominal Day 60 (NCT01140191)
Timeframe: Day 60

InterventionParticipants (Count of Participants)
WR 279,3961

[back to top]

Complete Cure of Index Lesion by Day 100

Number of participants with complete cure of index lesion by day 100. Cure rate is defined as 100% re-epithelialization of an ulcerated lesion (NCT01140191)
Timeframe: 100 days

InterventionParticipants (Count of Participants)
WR 279,3961

[back to top]

Cures of All Other Lesions

Number of participants with 100% re-epithelialization of all ulcerated lesions and resolution of all other types of lesions (NCT01140191)
Timeframe: 100 days

InterventionParticipants (Count of Participants)
WR 279,3960

[back to top]

Number of Adverse Events

Application site reactions including elicited question about pain, and clinician examination for erythema/redness and swelling/edema Blood chemistries and hematology Vital signs (NCT01140191)
Timeframe: 3 months

InterventionAdverse Events (Number)
WR 279,3963

[back to top]

Number of Participants Demonstrating Initial Clinical Improvements

Number of participants with > 50% re-epithelialization of index lesion by Day 60 followed by complete re-epithelialization of index lesion on or before nominal Day 100; (NCT01140191)
Timeframe: 60-100 days

InterventionParticipants (Count of Participants)
WR 279,3961

[back to top]

Number of Participants With No Relapse of Index Lesion Between Nominal Day 60 and 100

Number of participants with no relapses of lesion between 60 and 100 days. Relapse is defined as a 10% or greater increase in the area of ulceration of the index lesion or a shift from 100% re-epithelialization to < 100% re-epithelialization of the index lesion at Day 100 for those subjects that had 100% re-epithelialization of the index lesion at nominal Day 60 or before (NCT01140191)
Timeframe: 60-100 days

InterventionParticipants (Count of Participants)
WR 279,3960

[back to top]

Area of Index Lesions Throughout the Study

Area (mm^2) of index lesion on Days 0, 20, 28, 42, and 98. (NCT01494350)
Timeframe: Measured at day 0, 20, 28, 42, and 98

Interventionmm^2 (Mean)
Baseline (Day 0)Day 20Day 28Day 42Day 98
WR 279,396 Topical Cream12139320338.97.88

[back to top]

Number of Index Lesions With Reepithelialization Throughout the Study

Number of index lesions with 100% reepithelialization on Days 28 and 42. (NCT01494350)
Timeframe: Measured at day 28 and 42

Interventionlesions (Number)
Day 28Day 42
WR 279,396 Topical Cream828

[back to top]

Final Clinical Cure Rate for the Index Lesion

Number of index lesions with 100% reepithelialization at Day 98. (NCT01494350)
Timeframe: Final clincial cure is measured at day 98

Interventionlesions (Number)
WR 279,396 Topical Cream48

[back to top]

Number of All Ulcerated Lesions With Reepithelialization on Day 28

Final cure rate for all ulcerated lesions (100% reepithelialization for ulcerative lesions) on Day 28 (NCT01494350)
Timeframe: Measured on day 28

Interventionlesions (Number)
WR 279,396 Topical Cream23

[back to top]

Area of All Ulcerated Lesions Throughout the Study

Area of all ulcerated lesions on Days 20, 28, 42, and 98. (NCT01494350)
Timeframe: Measured at day 20, 28, 42 and 98

Interventionmm^2 (Mean)
Baseline (Day 0)Day 20Day 28Day 42Day 98
WR 279,396 Topical Cream82.628814922.14.02

[back to top]

Median Time to Initial Clinical Cure for Index Lesions

Median time to initial clinical cure for index lesions (100% re-epithelialization of the index lesion) (NCT01790659)
Timeframe: When 100% re-epithelialization of the index lesion is observed at any visit Study Days (20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days

InterventionDays (Median)
WR 279,39636.000
Paromomycin48.000

[back to top]

Percent of Participants With Final Clinical Cure

"The primary efficacy endpoint is percent of subjects with final clinical cure. Final clinical cure is defined as follows:~Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,~Subject has initial clinical improvement (> 50% re-epithelialization of index lesion by nominal Day 63) followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,~Subject has no relapse of index lesion." (NCT01790659)
Timeframe: baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days

Interventionpercent of participants (Number)
WR 279,39678.6
Paromomycin77.8

[back to top]

Percentage of All Lesions Cured at Day 168 (Ignores Per Subject Cure Rate)

Percentage of all lesions meeting criteria for clinical cure during the study at 168 day mark for mITT subjects (NCT01790659)
Timeframe: Day 168

Interventionpercentage of lesions (Number)
WR 279,39677.2
Paromomycin83.3

[back to top]

Percentage of Subjects With All Lesions Cured

• Percentage of subjects with all lesions cured, defined as: Final clinical cure as defined in primary objective (which is based solely on the index lesion); AND, Cure of all other lesions by nominal Day 100 (100% re-epithelialization of all ulcerated lesions and resolution of all other types of lesions) (NCT01790659)
Timeframe: 100 ± 14 days

Interventionpercentage of participants (Number)
WR 279,39675.1
Paromomycin76.3

[back to top]

Area of Ulceration (mm^2) All Treated Lesions at Each Measurement Time Point

Area of ulceration (mm^2) of all treated lesions from baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days for mITT subjects. Data presented is as presented in the Final Clinical Study Report; any inconsistencies can't be changed. (NCT01790659)
Timeframe: baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days

,
Interventionmm^2 (Mean)
Day 1Day 20Change from baseline Day 20Day 35Change from baseline Day 35Day 49Change from baseline Day 49Day 63Change from baseline Day 63Day 100Change from baseline Day 100Day 168Change from baseline Day 168
Paromomycin11569957766.1-51.923.9-92.115.8-98.74.64-1090.83-114
WR 279,39611565653353.0-62.821.4-93.819.9-96.27.49-1139.14-118

[back to top]

Area of Ulceration (mm^2) of the Index Lesion at Each Measurement Time Point

Area of ulceration (mm^2) of the index lesion at each measurement time point for mITT subjects (NCT01790659)
Timeframe: baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days

,
Interventionmm^2 (Mean)
Day 1Day 20Change from baseline Day 20Day 35Change from baseline Day 35Day 49Change from baseline Day 49Day 63Change from baseline Day 63Day 100Change from baseline Day 100Day 168Change from baseline Day 168
Paromomycin16592876296.1-69.933.9-13227.6-1367.41-1521.37-160
WR 279,39615383167768.3-84.129.4-12329.9-12312.5-14413.3-147

[back to top]